Morgan Stanley disclosed a 5.2% stake in Immunic, Inc., signaling increased interest in the pharmaceutical preparations sector.
| Name | IMMUNIC, INC. |
|---|---|
| CIK | 0001280776 |
| Tickers | IMUX |
| Exchanges | Nasdaq |
| Entity type | operating |
| Category | Non-accelerated filer<br>Smaller reporting company |
| SIC | 2834 Pharmaceutical Preparations |
| EIN | 562358443 |
| LEI | — |
| Fiscal year end | 1231 |
| State of incorporation | DE DE |
| Phone | (332) 255-9818 |
| Website | — |
| Investor website | — |
| Owner org | 03 Life Sciences |
| Flags | — |
| Description | — |
| Insider transactions (issuer) | 1 |
| Insider transactions (owner) | 0 |
EDGAR has no company-logo API. Website field is shown when the filer provided one.
Morgan Stanley disclosed a 5.2% stake in Immunic, Inc., signaling increased interest in the pharmaceutical preparations sector.
Immunic, Inc. releases its Q3 2026 financial report, highlighting developments in the pharmaceutical sector and future strategies.
Immunic, Inc. shares its Q3 financial results and updates on clinical trials for Vidofludimus Calcium, signaling a pivotal moment for the company.
Immunic, Inc. hosted a webinar on November 5, 2026, discussing its research on progressive multiple sclerosis, emphasizing its role in pharmaceutical preparations.
837 filing rows loaded from submissions recent.
| Filed | Form | Document | Items | Accession | File no. | Film | Act | Size | XBRL | iXBRL |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-16 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000947871-26-001032 | 005-88651 | 261563240 | 34 | 18044 | |||
| 2026-11-16 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001104659-26-128375 | 005-88651 | 261561511 | 34 | 20037 | |||
| 2026-11-13 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0000895421-26-000348 | 005-88651 | 261554117 | 34 | 8002 | |||
| 2026-11-13 | 8-K | 8-K | 2.02,9.01 | 0001493152-26-051543 | 001-36201 | 261549058 | 34 | 306180 | 1 | 1 |
| 2026-11-13 | 10-Q | 10-Q | 0001280776-26-000021 | 001-36201 | 261548983 | 34 | 14097913 | 1 | 1 | |
| 2026-11-05 | 8-K | e665870_8k-immunic.htm | 7.01,9.01 | 0001193805-26-001432 | 001-36201 | 261525098 | 34 | 10629141 | 1 | 1 |
| 2026-11-02 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001716774-26-000028 | 005-88651 | 261510050 | 34 | 9018 | |||
| 2026-10-01 | S-8 | e665795_s8-immunic.htm | 0001193805-26-001316 | 333-299232 | 261431352 | 33 | 418301 | 1 | 1 | |
| 2026-09-18 | 4 | xslF345X06/e665786_4-thorvald.xml | 0001193805-26-001256 | 6077 | ||||||
| 2026-09-18 | 4 | OWNERSHIP DOCUMENT | 0000921895-26-002590 | 28874 | ||||||
| 2026-09-11 | 8-K | e665777_8k-immunic.htm | 5.02,9.01 | 0001193805-26-001219 | 001-36201 | 261375264 | 34 | 187131 | 1 | 1 |
| 2026-09-09 | 8-K | e665768_8k-immunic.htm | 7.01,9.01 | 0001193805-26-001196 | 001-36201 | 261366882 | 34 | 11499399 | 1 | 1 |
| 2026-08-14 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0000947871-26-000800 | 005-88651 | 261283939 | 34 | 19166 | |||
| 2026-08-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001104659-26-097293 | 005-88651 | 261283062 | 34 | 11169 | |||
| 2026-08-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001831942-26-000038 | 005-88651 | 261282046 | 34 | 15850 | |||
| 2026-08-13 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001213900-26-088748 | 005-88651 | 261270261 | 34 | 21539 | |||
| 2026-08-12 | S-8 | e665620_s8-immunic.htm | 0001193805-26-001078 | 333-298264 | 261267437 | 33 | 229782 | 1 | 1 | |
| 2026-08-11 | 8-K | e665684_8k-immunic.htm | 2.02,5.02,7.01,9.01 | 0001193805-26-001071 | 001-36201 | 261260588 | 34 | 381263 | 1 | 1 |
| 2026-08-11 | 10-Q | 10-Q | 0001280776-26-000018 | 001-36201 | 261260551 | 34 | 13743237 | 1 | 1 | |
| 2026-08-10 | 4 | xslF345X06/e665686_4-ridloff.xml | 0001193805-26-001069 | 5553 | ||||||
| 2026-08-10 | 3 | xslF345X06/e665685_3-ridloff.xml | 0001193805-26-001068 | 3256 | ||||||
| 2026-08-06 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001104659-26-092235 | 005-88651 | 261251027 | 34 | 19834 | |||
| 2026-08-04 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0001390202-26-000013 | 005-88651 | 261240485 | 34 | 12392 | |||
| 2026-07-16 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001716774-26-000017 | 005-88651 | 261178636 | 34 | 9111 | |||
| 2026-07-14 | 8-K | e665650_8k-immunic.htm | 7.01,9.01 | 0001193805-26-000966 | 001-36201 | 261172563 | 34 | 7555611 | 1 | 1 |
| 2026-07-07 | 4 | xslF345X06/e665635_4-skerjanec.xml | 0001193805-26-000932 | 5565 | ||||||
| 2026-07-07 | 4 | xslF345X06/e665634_4-rudick.xml | 0001193805-26-000931 | 5526 | ||||||
| 2026-07-07 | 4 | xslF345X06/e665633_4-phillips.xml | 0001193805-26-000930 | 5540 | ||||||
| 2026-07-07 | 4 | xslF345X06/e665632_4-jorg.xml | 0001193805-26-000929 | 5518 | ||||||
| 2026-07-07 | 4 | xslF345X06/e665631_4-congleton.xml | 0001193805-26-000928 | 5522 | ||||||
| 2026-07-06 | 8-K | e665619_8k-immunic.htm | 5.02 | 0001193805-26-000916 | 001-36201 | 261156204 | 34 | 187167 | 1 | 1 |
| 2026-06-29 | 4 | xslF345X06/e665612_4-congleton.xml | 0001193805-26-000892 | 5992 | ||||||
| 2026-06-29 | 4 | xslF345X06/e665611_4-skerjanec.xml | 0001193805-26-000891 | 5965 | ||||||
| 2026-06-29 | 4 | xslF345X06/e665610_4-rudick.xml | 0001193805-26-000890 | 5926 | ||||||
| 2026-06-29 | 4 | xslF345X06/e665609_4-howson.xml | 0001193805-26-000889 | 5794 | ||||||
| 2026-06-29 | 4 | xslF345X06/e665608_4-jorg.xml | 0001193805-26-000888 | 5918 | ||||||
| 2026-06-29 | 4 | xslF345X06/e665607_4-phillips.xml | 0001193805-26-000887 | 5940 | ||||||
| 2026-06-29 | 4 | xslF345X06/e665606_4-jason.xml | 0001193805-26-000886 | 6022 | ||||||
| 2026-06-29 | 4 | FORM 4 | 0001193805-26-000885 | 6120 | ||||||
| 2026-06-29 | 4 | xslF345X06/e665604_4-vitt.xml | 0001193805-26-000884 | 6033 | ||||||
| 2026-06-29 | 4 | xslF345X06/e665603_4-bonney.xml | 0001193805-26-000883 | 6008 | ||||||
| 2026-06-29 | 8-K | e665616_8k-immunic.htm | 5.02,5.07,9.01 | 0001193805-26-000882 | 001-36201 | 261135731 | 34 | 441906 | 1 | 1 |
| 2026-06-01 | 4 | xslF345X06/e665512_4-lundgren.xml | 0001193805-26-000731 | 5975 | ||||||
| 2026-06-01 | 3 | xslF345X06/e665511_3-lundgren.xml | 0001193805-26-000730 | 637413 | ||||||
| 2026-05-29 | DEF 14A | e665517_def14a-immunic.htm | 0001193805-26-000719 | 001-36201 | 261045235 | 34 | 1072825 | |||
| 2026-05-28 | 8-K | e665514_8k-immunic.htm | 7.01,9.01 | 0001193805-26-000703 | 001-36201 | 261028530 | 34 | 3056612 | 1 | 1 |
| 2026-05-27 | 8-K | e665513_8k-immunic.htm | 5.02,7.01,9.01 | 0001193805-26-000696 | 001-36201 | 261022135 | 34 | 372785 | 1 | 1 |
| 2026-05-19 | 3 | xslF345X06/e665491_3-bonney.xml | 0001193805-26-000660 | 17836 | ||||||
| 2026-05-19 | 8-K | e665479_8k-immunic.htm | 5.02,7.01,9.01 | 0001193805-26-000645 | 001-36201 | 26995847 | 34 | 223165 | 1 | 1 |
| 2026-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001172661-26-002364 | 005-88651 | 26988712 | 34 | 11298 | |||
| 2026-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000921895-26-001364 | 005-88651 | 26983860 | 34 | 11786 | |||
| 2026-05-13 | 8-K | e665461_8k-immunic.htm | 2.02,9.01 | 0001193805-26-000593 | 001-36201 | 26970873 | 34 | 263013 | 1 | 1 |
| 2026-05-13 | 10-Q | 10-Q | 0001280776-26-000010 | 001-36201 | 26970823 | 34 | 12845148 | 1 | 1 | |
| 2026-05-06 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0001104659-26-056411 | 005-88651 | 26950045 | 34 | 18676 | |||
| 2026-05-04 | EFFECT | xslEFFECTX01/primary_doc.xml | ,, | 9999999995-26-001473 | 333-294855 | 26940133 | 33 | 1847 | ||
| 2026-05-01 | CORRESP | filename1.htm | 0001193805-26-000555 | 11584 | ||||||
| 2026-04-30 | S-3/A | e665413_s3a-immunic.htm | 0001193805-26-000550 | 333-294855 | 26927214 | 33 | 323992 | |||
| 2026-04-29 | 4 | xslF345X06/e665406_4-panzara.xml | 0001193805-26-000529 | 5861 | ||||||
| 2026-04-29 | 3 | xslF345X06/e665405_3-panzara.xml | 0001193805-26-000527 | 23626 | ||||||
| 2026-04-28 | 8-K | e665394_8k-immunic.htm | 5.02,7.01,9.01 | 0001193805-26-000516 | 001-36201 | 26903070 | 34 | 440603 | 1 | 1 |
| 2026-04-23 | 8-K | e665386_8k-immunic.htm | 3.03,5.03,8.01,9.01 | 0001193805-26-000495 | 001-36201 | 26885710 | 34 | 223531 | 1 | 1 |
| 2026-04-22 | 10-K/A | e665391_10ka-immunic.htm | 0001193805-26-000493 | 001-36201 | 26884513 | 34 | 752822 | 1 | 1 | |
| 2026-04-17 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0000919574-26-002262 | 005-88651 | 26869953 | 34 | 27161 | |||
| 2026-04-14 | 8-K | e665361_8k-immunic.htm | 5.07,8.01 | 0001193805-26-000461 | 001-36201 | 26860867 | 34 | 188097 | 1 | 1 |
| 2026-04-10 | 8-K | e665332_8k-immunic.htm | 5.02,9.01 | 0001193805-26-000437 | 001-36201 | 26854846 | 34 | 220314 | 1 | 1 |
| 2026-04-09 | S-8 | e665230_s8-immunic.htm | 0001193805-26-000426 | 333-294952 | 26852019 | 33 | 438674 | 1 | 1 | |
| 2026-04-06 | UPLOAD | filename1.pdf | 0000000000-26-003455 | 333-294855 | 40136 | |||||
| 2026-04-02 | S-3 | e665266_s3-immunic.htm | 0001193805-26-000400 | 333-294855 | 26834283 | 33 | 619268 | 1 | 1 | |
| 2026-04-01 | 8-K | e665306_8k-immunic.htm | 8.01,9.01 | 0001193805-26-000382 | 001-36201 | 26824649 | 34 | 205716 | 1 | 1 |
| 2026-03-31 | 3 | xslF345X06/e665297_3-congleton.xml | 0001193805-26-000381 | 3227 | ||||||
| 2026-03-31 | 8-K | e665296_8k-immunic.htm | 5.02,7.01,9.01 | 0001193805-26-000370 | 001-36201 | 26816818 | 34 | 217614 | 1 | 1 |
| 2026-03-04 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001172661-26-001332 | 005-88651 | 26721442 | 34 | 14223 | |||
| 2026-03-04 | D | xslFormDX01/primary_doc.xml | 06b | 0001193805-26-000217 | 021-575474 | 26721252 | 33 | 28713 | ||
| 2026-03-02 | DEF 14A | e665189_def14a-immunic.htm | 0001193805-26-000201 | 001-36201 | 26708199 | 34 | 233202 | |||
| 2026-02-27 | 3 | OWNERSHIP DOCUMENT | 0000921895-26-000568 | 40961 | ||||||
| 2026-02-27 | 3 | OWNERSHIP DOCUMENT | 0000921895-26-000567 | 3079 | ||||||
| 2026-02-26 | 10-K | 10-K | 0001280776-26-000005 | 001-36201 | 26681695 | 34 | 25477687 | 1 | 1 | |
| 2026-02-26 | 8-K | e665186_8k-immunic.htm | 2.02,9.01 | 0001193805-26-000181 | 001-36201 | 26681631 | 34 | 263524 | 1 | 1 |
| 2026-02-24 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001831942-26-000012 | 005-88651 | 26672349 | 34 | 15913 | |||
| 2026-02-24 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001493152-26-007882 | 005-88651 | 26671764 | 34 | 24497 | |||
| 2026-02-20 | SCHEDULE 13D | xslSCHEDULE_13D_X01/primary_doc.xml | 0000921895-26-000531 | 005-88651 | 26661737 | 34 | 65361 | |||
| 2026-02-20 | PRE 14A | e665172_pre14a-immunic.htm | 0001193805-26-000167 | 001-36201 | 26661031 | 34 | 227241 | |||
| 2026-02-20 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001213900-26-018848 | 005-88651 | 26660812 | 34 | 22776 | |||
| 2026-02-19 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001213900-26-018443 | 005-88651 | 26654902 | 34 | 47280 | |||
| 2026-02-17 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001172661-26-001176 | 005-88651 | 26642661 | 34 | 10826 | |||
| 2026-02-17 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000921895-26-000467 | 005-88651 | 26641671 | 34 | 10760 | |||
| 2026-02-13 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001104659-26-015336 | 005-88651 | 26634383 | 34 | 11095 | |||
| 2026-02-13 | 8-K | e665154_8k-immunic.htm | 1.01,3.02,5.02,8.01,9.01 | 0001193805-26-000129 | 001-36201 | 26628842 | 34 | 1344545 | 1 | 1 |
| 2026-02-02 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001716774-26-000009 | 005-88651 | 26586231 | 34 | 8922 | |||
| 2026-01-06 | 8-K | e665076_8k-immunic.htm | 3.01 | 0001193805-26-000011 | 001-36201 | 26511439 | 34 | 188527 | 1 | 1 |
| 2026-01-05 | 8-K | e665087_8k-immunic.htm | 5.02,9.01 | 0001193805-26-000007 | 001-36201 | 26507478 | 34 | 425227 | 1 | 1 |
| 2025-12-08 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001274173-25-000336 | 005-88651 | 251555161 | 34 | 10004 | |||
| 2025-11-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001172661-25-005186 | 005-88651 | 251489015 | 34 | 10837 | |||
| 2025-11-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000919574-25-006917 | 005-88651 | 251484112 | 34 | 24107 | |||
| 2025-11-13 | 8-K | e664954_8k-immunic.htm | 2.02,9.01 | 0001193805-25-001570 | 001-36201 | 251475403 | 34 | 280201 | 1 | 1 |
| 2025-11-13 | 10-Q | 10-Q | 0001280776-25-000017 | 001-36201 | 251475388 | 34 | 13231499 | 1 | 1 | |
| 2025-11-07 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001213900-25-107607 | 005-88651 | 251462437 | 34 | 29047 | |||
| 2025-09-25 | 8-K | e664856_8k-immunic.htm | 8.01,9.01 | 0001193805-25-001357 | 001-36201 | 251340217 | 34 | 3619221 | 1 | 1 |
| 2025-08-27 | S-8 | e664796_s8-immunic.htm | 0001193805-25-001239 | 333-289884 | 251265245 | 33 | 229139 | 1 | 1 | |
| 2025-08-14 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001172661-25-003550 | 005-88651 | 251221345 | 34 | 11148 | |||
| 2025-08-14 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001104659-25-078722 | 005-88651 | 251220338 | 34 | 11356 | |||
| 2025-08-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000921895-25-002282 | 005-88651 | 251218549 | 34 | 29938 | |||
| 2025-08-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000919574-25-004879 | 005-88651 | 251217624 | 34 | 27614 | |||
| 2025-08-12 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000902664-25-003508 | 005-88651 | 251204579 | 34 | 13123 | |||
| 2025-08-08 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0000921895-25-002136 | 005-88651 | 251198364 | 34 | 15993 | |||
| 2025-08-07 | 10-Q | 10-Q | 0001280776-25-000012 | 001-36201 | 251191474 | 34 | 12593794 | 1 | 1 | |
| 2025-08-07 | 8-K | e664768_8k-immunic.htm | 2.02,8.01,9.01 | 0001193805-25-001164 | 001-36201 | 251191442 | 34 | 16121688 | 1 | 1 |
| 2025-07-31 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001085146-25-004384 | 005-88651 | 251171436 | 34 | 8782 | |||
| 2025-07-18 | 4 | FORM 4 | 0001193805-25-001069 | 15616 | ||||||
| 2025-07-18 | 4 | xslF345X05/e664708_4-duane.xml | 0001193805-25-001068 | 15574 | ||||||
| 2025-07-18 | 4 | xslF345X05/e664707_4-vitt.xml | 0001193805-25-001067 | 15551 | ||||||
| 2025-07-18 | 4 | xslF345X05/e664706_4-muehler.xml | 0001193805-25-001066 | 15578 | ||||||
| 2025-07-18 | 4 | xslF345X05/e664705_4-jason.xml | 0001193805-25-001065 | 15518 | ||||||
| 2025-07-11 | 8-K | e664690_8k-immunic.htm | 5.02 | 0001193805-25-001008 | 001-36201 | 251119550 | 34 | 188193 | 1 | 1 |
| 2025-06-27 | 8-K | e664657_8k-immunic.htm | 3.01 | 0001193805-25-000943 | 001-36201 | 251087854 | 34 | 188606 | 1 | 1 |
| 2025-06-20 | 4/A | xslF345X05/e664640_4a-jason.xml | 0001193805-25-000925 | 7322 | ||||||
| 2025-06-20 | 4/A | FORM 4 | 0001193805-25-000924 | 5889 | ||||||
| 2025-06-20 | 4/A | xslF345X05/e664638_4a-vitt.xml | 0001193805-25-000923 | 8570 | ||||||
| 2025-06-20 | 4/A | xslF345X05/e664637_4a-duane.xml | 0001193805-25-000922 | 5721 | ||||||
| 2025-06-20 | 4/A | xslF345X05/e664636_4a-muehler.xml | 0001193805-25-000921 | 5851 | ||||||
| 2025-06-16 | 4 | xslF345X05/e664632_4-duane.xml | 0001193805-25-000885 | 5096 | ||||||
| 2025-06-09 | 4 | xslF345X05/e664612_4-howson.xml | 0001193805-25-000843 | 5261 | ||||||
| 2025-06-09 | 4 | xslF345X05/e664611_4-skerjanec.xml | 0001193805-25-000842 | 5432 | ||||||
| 2025-06-09 | 4 | xslF345X05/e664610_4-rudick.xml | 0001193805-25-000841 | 5393 | ||||||
| 2025-06-09 | 4 | xslF345X05/e664609_4-toernsen.xml | 0001193805-25-000840 | 5432 | ||||||
| 2025-06-09 | 4 | xslF345X05/e664608_4-jason.xml | 0001193805-25-000839 | 7022 | ||||||
| 2025-06-09 | 4 | xslF345X05/e664607_4-jorg.xml | 0001193805-25-000838 | 5385 | ||||||
| 2025-06-09 | 4 | FORM 4 | 0001193805-25-000837 | 5589 | ||||||
| 2025-06-09 | 4 | xslF345X05/e664604_4-duane.xml | 0001193805-25-000836 | 5421 | ||||||
| 2025-06-09 | 4 | xslF345X05/e664603_4-phillips.xml | 0001193805-25-000835 | 5407 | ||||||
| 2025-06-09 | 4 | xslF345X05/e664602_4-muehler.xml | 0001193805-25-000834 | 5551 | ||||||
| 2025-06-06 | 4 | xslF345X05/e664605_4-vitt.xml | 0001193805-25-000821 | 8270 | ||||||
| 2025-06-05 | 4 | xslF345X05/e664594_4-jorg.xml | 0001193805-25-000800 | 7057 | ||||||
| 2025-06-04 | 4 | FORM 4 | 0001193805-25-000788 | 7153 | ||||||
| 2025-06-04 | 8-K | e664589_8k-immunic.htm | 5.02,5.07,9.01 | 0001193805-25-000787 | 001-36201 | 251023183 | 34 | 470309 | 1 | 1 |
| 2025-06-04 | 4 | xslF345X05/e664585_4-rudick.xml | 0001193805-25-000786 | 5071 | ||||||
| 2025-05-30 | 8-K | FORM 8-K | 1.01,7.01,9.01 | 0001193805-25-000757 | 001-36201 | 251011726 | 34 | 973858 | 1 | 1 |
| 2025-05-30 | 424B5 | e664565_424b5-immunic.htm | 0001193805-25-000756 | 333-275717 | 251011711 | 33 | 741959 | |||
| 2025-05-28 | 424B5 | e664548_424b5-immunic.htm | 0001193805-25-000731 | 333-275717 | 25996155 | 33 | 737043 | |||
| 2025-05-28 | 8-K | e664552_8k-immuniclaunch.htm | 8.01,9.01 | 0001193805-25-000730 | 001-36201 | 25995556 | 34 | 4709888 | 1 | 1 |
| 2025-05-15 | 10-Q | 10-Q | 0001280776-25-000008 | 001-36201 | 25952907 | 34 | 11909801 | 1 | 1 | |
| 2025-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000919574-25-003220 | 005-88651 | 25951325 | 34 | 25506 | |||
| 2025-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000950170-25-072015 | 005-88651 | 25948802 | 34 | 10568 | |||
| 2025-04-30 | 8-K | e664445_8k-immunic.htm | 8.01,9.01 | 0001193805-25-000582 | 001-36201 | 25891014 | 34 | 9406213 | 1 | 1 |
| 2025-04-22 | DEFA14A | e664424_defa14a-immunic.htm | 0001193805-25-000542 | 001-36201 | 25858564 | 34 | 281060 | |||
| 2025-04-22 | DEF 14A | e664292_def14a-immunic.htm | 0001193805-25-000541 | 001-36201 | 25858555 | 34 | 960441 | |||
| 2025-04-09 | 424B5 | e664312_424b5-immunic.htm | 0001193805-25-000455 | 333-275717 | 25826005 | 33 | 594670 | |||
| 2025-04-09 | 8-K | e664373_8k-immunic.htm | 1.01,3.02,7.01,9.01 | 0001193805-25-000454 | 001-36201 | 25825989 | 34 | 665830 | 1 | 1 |
| 2025-03-31 | 10-K | 10-K | 0001280776-25-000005 | 001-36201 | 25789201 | 34 | 21891989 | 1 | 1 | |
| 2025-02-20 | 8-K | e664213_8k-immunic.htm | 8.01,9.01 | 0001193805-25-000212 | 001-36201 | 25643282 | 34 | 3655406 | 1 | 1 |
| 2025-02-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001274173-25-000049 | 005-88651 | 25625180 | 34 | 9646 | |||
| 2025-02-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000919574-25-001377 | 005-88651 | 25624428 | 34 | 26524 | |||
| 2025-02-12 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000902664-25-000878 | 005-88651 | 25612697 | 34 | 12571 | |||
| 2025-01-30 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000932471-25-000155 | 005-88651 | 25575633 | 34 | 6344 | |||
| 2025-01-13 | 8-K | e664134_8k-immunic.htm | 8.01,9.01 | 0001193805-25-000038 | 001-36201 | 25524976 | 34 | 17001358 | 1 | 1 |
| 2024-12-18 | 8-K | e664091_8k-immunic.htm | 5.02,9.01 | 0001193805-24-001496 | 001-36201 | 241559784 | 34 | 1079687 | 1 | 1 |
| 2024-12-09 | 4/A | xslF345X05/e664066_4a-duane.xml | 0001193805-24-001448 | 5748 | ||||||
| 2024-12-06 | 4 | xslF345X05/e664062_4-duane.xml | 0001193805-24-001444 | 5552 | ||||||
| 2024-12-06 | 4 | xslF345X05/e664061_4-muehler.xml | 0001193805-24-001443 | 5556 | ||||||
| 2024-12-06 | 4 | xslF345X05/e664060_4-jason.xml | 0001193805-24-001442 | 5521 | ||||||
| 2024-12-06 | 4 | xslF345X05/e664059_4-vitt.xml | 0001193805-24-001441 | 5523 | ||||||
| 2024-12-06 | 4 | FORM 4 | 0001193805-24-001440 | 5594 | ||||||
| 2024-11-14 | SC 13G/A | d11530437_13g-a.htm | 0000919574-24-006770 | 005-88651 | 241464611 | 34 | 165851 | |||
| 2024-11-14 | SC 13G/A | JANUS AMENDMENT | 0001274173-24-000115 | 005-88651 | 241459419 | 34 | 13138 | |||
| 2024-11-14 | SC 13G/A | p24-3275sc13ga.htm | 0000902664-24-006505 | 005-88651 | 241457043 | 34 | 63641 | |||
| 2024-11-13 | 4 | xslF345X05/e664024_4-rudick.xml | 0001193805-24-001335 | 4610 | ||||||
| 2024-11-12 | SC 13G/A | UnitedStates_13G__ImmunicInc.txt | 0000932471-24-001034 | 005-88651 | 241447584 | 34 | 6637 | |||
| 2024-11-12 | SC 13G | IMMUNIC, INC. | 0000902664-24-006400 | 005-88651 | 241444197 | 34 | 80737 | |||
| 2024-11-07 | 10-Q | 10-Q | 0001280776-24-000018 | 001-36201 | 241433086 | 34 | 11532008 | 1 | 1 | |
| 2024-11-07 | 8-K | e663991_8k-immunic.htm | 2.02,8.01,9.01 | 0001193805-24-001316 | 001-36201 | 241433035 | 34 | 4254814 | 1 | 1 |
| 2024-11-04 | SC 13G/A | UnitedStates_13G__ImmunicInc.txt | 0000932471-24-000433 | 005-88651 | 241421705 | 34 | 5717 | |||
| 2024-10-22 | 8-K | e663960_8k-immunic.htm | 8.01,9.01 | 0001193805-24-001257 | 001-36201 | 241384641 | 34 | 3604256 | 1 | 1 |
| 2024-09-10 | 8-K | e663880_8k-immunic.htm | 8.01,9.01 | 0001193805-24-001102 | 001-36201 | 241290124 | 34 | 18099914 | 1 | 1 |
| 2024-09-03 | 8-K | e663859_8k-immunic.htm | 1.01,9.01 | 0001193805-24-001079 | 001-36201 | 241272120 | 34 | 202243 | 1 | 1 |
| 2024-08-08 | 10-Q | 10-Q | 0001280776-24-000014 | 001-36201 | 241186034 | 34 | 11453023 | 1 | 1 | |
| 2024-08-08 | 8-K | e663826_8k-immunic.htm | 2.02,8.01,9.01 | 0001193805-24-001007 | 001-36201 | 241185909 | 34 | 3811950 | 1 | 1 |
| 2024-07-24 | 4 | xslF345X05/e663799_4-skerjanec.xml | 0001193805-24-000961 | 8021 | ||||||
| 2024-07-24 | 3 | xslF345X02/e663798_3-skerjanec.xml | 0001193805-24-000960 | 3166 | ||||||
| 2024-07-24 | 8-K | e663800_8k-immunic.htm | 5.02,9.01 | 0001193805-24-000957 | 001-36201 | 241136058 | 34 | 231722 | 1 | 1 |
| 2024-07-12 | 4 | xslF345X05/e663770_4-jason.xml | 0001193805-24-000914 | 5661 | ||||||
| 2024-07-12 | 3 | xslF345X02/e663769_3-jason.xml | 0001193805-24-000913 | 3099 | ||||||
| 2024-07-09 | 8-K | e663765_8k-immunic.htm | 5.02,9.01 | 0001193805-24-000893 | 001-36201 | 241106299 | 34 | 236805 | 1 | 1 |
| 2024-07-02 | S-8 | e663743_s8-immunic.htm | 0001193805-24-000874 | 333-280661 | 241095247 | 33 | 463765 | |||
| 2024-06-13 | 8-K | e663709_8k-immunic.htm | 5.07 | 0001193805-24-000791 | 001-36201 | 241039660 | 34 | 199653 | 1 | 1 |
| 2024-06-12 | 4 | xslF345X05/e663707_4-jorg.xml | 0001193805-24-000788 | 5390 | ||||||
| 2024-06-12 | 4 | xslF345X05/e663706_4-phillips.xml | 0001193805-24-000787 | 5412 | ||||||
| 2024-06-12 | 4 | xslF345X05/e663705_4-rudick.xml | 0001193805-24-000786 | 5398 | ||||||
| 2024-06-12 | 4 | xslF345X05/e663704_4-toernsen.xml | 0001193805-24-000785 | 5437 | ||||||
| 2024-06-12 | 4 | xslF345X05/e663703_4-howson.xml | 0001193805-24-000784 | 5266 | ||||||
| 2024-06-10 | 424B5 | e663697_424b5-immunic.htm | 0001193805-24-000772 | 333-275717 | 241032682 | 33 | 425613 | |||
| 2024-05-31 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2024-05-31 17:00:00 | 9999999995-24-001689 | 333-275717 | 241011839 | 33 | 1855 | ||
| 2024-05-29 | CORRESP | filename1.htm | 0001193805-24-000720 | 5258 | ||||||
| 2024-05-24 | S-3/A | PRE-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 | 0001193805-24-000704 | 333-275717 | 24984297 | 33 | 376745 | |||
| 2024-05-08 | 10-Q | 10-Q | 0001280776-24-000009 | 001-36201 | 24924240 | 34 | 5434038 | 1 | 1 | |
| 2024-05-08 | 8-K | e663589_8k-immunic.htm | 2.02,8.01,9.01 | 0001193805-24-000605 | 001-36201 | 24924147 | 34 | 3907119 | 1 | 1 |
| 2024-04-30 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2024-04-30 17:00:00 | 9999999995-24-001212 | 333-277040 | 24899793 | 33 | 1854 | ||
| 2024-04-30 | 424B3 | e663565_424b3-immunic.htm | 0001193805-24-000582 | 333-277040 | 24898567 | 33 | 220843 | |||
| 2024-04-26 | CORRESP | filename1.htm | 0001193805-24-000570 | 5432 | ||||||
| 2024-04-23 | DEF 14A | e663535_def14a-immunic.htm | 0001193805-24-000551 | 001-36201 | 24865460 | 34 | 541374 | |||
| 2024-03-08 | 8-K | e619340_8k-immunic.htm | 5.03,5.07,9.01 | 0001193805-24-000341 | 001-36201 | 24734304 | 34 | 215750 | 1 | 1 |
| 2024-03-06 | 4 | xslF345X05/e619339_4-howson.xml | 0001193805-24-000325 | 16600 | ||||||
| 2024-03-06 | 4 | xslF345X05/e619338_4-duane.xml | 0001193805-24-000324 | 25219 | ||||||
| 2024-03-06 | 4 | xslF345X05/e619337_4-phillips.xml | 0001193805-24-000323 | 16734 | ||||||
| 2024-03-06 | 4 | xslF345X05/e619336_4-vitt.xml | 0001193805-24-000322 | 16743 | ||||||
| 2024-03-06 | 4 | xslF345X05/e619335_4-muehler.xml | 0001193805-24-000321 | 19140 | ||||||
| 2024-03-06 | 4 | FORM 4 | 0001193805-24-000320 | 21323 | ||||||
| 2024-03-06 | 4 | xslF345X05/e619333_4-joerg.xml | 0001193805-24-000319 | 14797 | ||||||
| 2024-03-06 | 4 | xslF345X05/e619332_4-toernsen.xml | 0001193805-24-000318 | 8401 | ||||||
| 2024-03-01 | S-3/A | e619307_s3a-immunic.htm | 0001193805-24-000288 | 333-277040 | 24709737 | 33 | 270411 | |||
| 2024-02-28 | 4 | xslF345X05/e619306_4-vitt.xml | 0001193805-24-000282 | 5257 | ||||||
| 2024-02-22 | 10-K | 10-K | 0001280776-24-000004 | 001-36201 | 24662213 | 34 | 15621333 | 1 | 1 | |
| 2024-02-22 | 8-K | e619294_8k-immunic.htm | 2.02,8.01,9.01 | 0001193805-24-000257 | 001-36201 | 24662211 | 34 | 4273753 | 1 | 1 |
| 2024-02-21 | UPLOAD | filename1.pdf | 0000000000-24-001995 | 333-277040 | 40357 | |||||
| 2024-02-14 | SC 13G/A | formsc13ga.htm | 0001493152-24-006624 | 005-88651 | 24637793 | 34 | 101903 | |||
| 2024-02-14 | SC 13G/A | deeptrack-imux123123a2.htm | 0001172661-24-000925 | 005-88651 | 24632660 | 34 | 103323 | |||
| 2024-02-14 | SC 13G/A | IMMUNIC, INC. | 0000902664-24-001577 | 005-88651 | 24632398 | 34 | 64200 | |||
| 2024-02-13 | S-3 | FORM S-3 | 0001193805-24-000203 | 333-277040 | 24626708 | 33 | 334988 | |||
| 2024-02-05 | DEF 14A | e619216_def14a-immunic.htm | 0001193805-24-000129 | 001-36201 | 24594145 | 34 | 675368 | |||
| 2024-01-24 | PRE 14A | e619200_pre14a-immunic.htm | 0001193805-24-000089 | 001-36201 | 24557403 | 34 | 654477 | |||
| 2024-01-19 | 4 | xslF345X05/e619199_4-duane.xml | 0001193805-24-000069 | 5425 | ||||||
| 2024-01-19 | 4 | xslF345X05/e619198_4-vitt.xml | 0001193805-24-000068 | 5532 | ||||||
| 2024-01-19 | 4 | xslF345X05/e619197_4-muehler.xml | 0001193805-24-000067 | 5555 | ||||||
| 2024-01-19 | 4 | FORM 4 | 0001193805-24-000066 | 5593 | ||||||
| 2024-01-19 | D | xslFormDX01/primary_doc.xml | 06b | 0001193805-24-000065 | 021-502974 | 24545604 | 33 | 17527 | ||
| 2024-01-18 | SC 13G | SCHEDULE 13G | 0000921895-24-000094 | 005-88651 | 24542064 | 34 | 287209 | |||
| 2024-01-18 | SC 13G | JHG PLC OWNS 7.4% | 0001274173-24-000002 | 005-88651 | 24540757 | 34 | 13070 | |||
| 2024-01-16 | SC 13G | d10934644_13g.htm | 0000919574-24-000383 | 005-88651 | 24535290 | 34 | 170762 | |||
| 2024-01-10 | SC 13G | SCHEDULE 13G | 0001213900-24-002473 | 005-88651 | 24525006 | 34 | 149970 | |||
| 2024-01-05 | 8-K | e619173_8k-immunic.htm | 1.01,3.02,7.01,8.01,9.01 | 0001193805-24-000022 | 001-36201 | 24514407 | 34 | 8988302 | 1 | 1 |
| 2023-12-21 | 8-K | e619130_8k-immunic.htm | 5.02,9.01 | 0001193805-23-001637 | 001-36201 | 231502884 | 34 | 923245 | 1 | 1 |
| 2023-11-30 | UPLOAD | filename1.pdf | 0000000000-23-013078 | 333-275717 | 40369 | |||||
| 2023-11-22 | S-3 | e619076_s3-immunic.htm | 0001193805-23-001527 | 333-275717 | 231433756 | 33 | 715024 | |||
| 2023-11-14 | 10-Q | 10-Q | 0001280776-23-000018 | 001-36201 | 231401578 | 34 | 5387908 | 1 | 1 | |
| 2023-11-14 | 8-K | e619056_8k-immunic.htm | 2.02,8.01,9.01 | 0001193805-23-001486 | 001-36201 | 231401464 | 34 | 4552431 | 1 | 1 |
| 2023-10-18 | 8-K | e619010_8k-immunic.htm | 1.01,9.01 | 0001193805-23-001425 | 001-36201 | 231332289 | 34 | 203206 | 1 | 1 |
| 2023-10-10 | 8-K | e618990_8k-immunic.htm | 8.01,9.01 | 0001193805-23-001384 | 001-36201 | 231315882 | 34 | 7232457 | 1 | 1 |
| 2023-08-21 | S-8 | e618885_s8-immunic.htm | 0001193805-23-001200 | 333-274099 | 231187259 | 33 | 362883 | |||
| 2023-08-03 | 10-Q | 10-Q | 0001280776-23-000013 | 001-36201 | 231137956 | 34 | 5310493 | 1 | 1 | |
| 2023-08-03 | 8-K | e618816_8k-immunic.htm | 2.02,8.01,9.01 | 0001193805-23-001054 | 001-36201 | 231137946 | 34 | 3855534 | 1 | 1 |
| 2023-06-30 | 8-K | e618747_8k-immunic.htm | 5.07 | 0001193805-23-000931 | 001-36201 | 231059616 | 34 | 199826 | 1 | 1 |
| 2023-06-29 | 4 | xslF345X04/e618746_4-howson.xml | 0001193805-23-000923 | 5181 | ||||||
| 2023-06-29 | 4 | xslF345X04/e618745_4-phillips.xml | 0001193805-23-000921 | 5327 | ||||||
| 2023-06-29 | 4 | xslF345X04/e618744_4-rudick.xml | 0001193805-23-000919 | 5313 | ||||||
| 2023-06-29 | 4 | xslF345X04/e618743_4-jorg.xml | 0001193805-23-000917 | 5304 | ||||||
| 2023-06-29 | 4 | xslF345X04/e618742_4-toernsen.xml | 0001193805-23-000915 | 5352 | ||||||
| 2023-05-16 | 4 | FORM 4 | 0001193805-23-000735 | 4831 | ||||||
| 2023-05-11 | 8-K | e618615_8k-immunic.htm | 2.02,8.01,9.01 | 0001193805-23-000700 | 001-36201 | 23909076 | 34 | 3879463 | 1 | 1 |
| 2023-05-11 | 10-Q | 10-Q | 0001280776-23-000010 | 001-36201 | 23908722 | 34 | 5518103 | 1 | 1 | |
| 2023-05-04 | 8-K | e618584_8k-immunic.htm | 8.01,9.01 | 0001193805-23-000659 | 001-36201 | 23886327 | 34 | 12186243 | 1 | 1 |
| 2023-05-01 | DEF 14A | e618561_def14a-immunic.htm | 0001193805-23-000637 | 001-36201 | 23874753 | 34 | 755918 | |||
| 2023-04-27 | 4 | xslF345X04/e618551_4-rudick.xml | 0001193805-23-000613 | 5315 | ||||||
| 2023-04-27 | 3 | xslF345X02/e618550_3-rudick.xml | 0001193805-23-000612 | 2957 | ||||||
| 2023-04-27 | 8-K | FORM 8-K | 5.02,9.01 | 0001193805-23-000611 | 001-36201 | 23851744 | 34 | 224660 | 1 | 1 |
| 2023-04-05 | 8-K | FORM 8-K | 8.01,9.01 | 0001193805-23-000500 | 001-36201 | 23801119 | 34 | 6379433 | 1 | 1 |
| 2023-03-13 | 8-K | FORM 8-K | 7.01 | 0001193805-23-000309 | 001-36201 | 23725823 | 34 | 196648 | 1 | 1 |
| 2023-02-24 | SC 13D/A | SC 13D/A | 0001193125-23-047459 | 005-88651 | 23662310 | 34 | 52124 | |||
| 2023-02-23 | 10-K | 10-K | 0001280776-23-000004 | 001-36201 | 23655865 | 34 | 7906650 | 1 | 1 | |
| 2023-02-23 | 8-K | e618296_8k-immunic.htm | 2.02,8.01,9.01 | 0001193805-23-000241 | 001-36201 | 23655846 | 34 | 2813406 | 1 | 1 |
| 2023-02-14 | SC 13G/A | formsc13ga.htm | 0001493152-23-004853 | 005-88651 | 23628836 | 34 | 103299 | |||
| 2023-02-14 | SC 13G/A | IMMUNIC, INC. | 0000902664-23-001718 | 005-88651 | 23623845 | 34 | 62107 | |||
| 2023-02-14 | SC 13G/A | deeptrack-imux123122a1.htm | 0001172661-23-000832 | 005-88651 | 23622931 | 34 | 103536 | |||
| 2023-02-13 | SC 13D/A | SC 13D/A | 0001193125-23-035951 | 005-88651 | 23619211 | 34 | 173517 | |||
| 2023-02-09 | 8-K | e618255_8k-immunic.htm | 8.01,9.01 | 0001193805-23-000100 | 001-36201 | 23601050 | 34 | 14071519 | 1 | 1 |
| 2023-01-20 | 8-K | FORM 8-K | 5.02,9.01 | 0001193805-23-000064 | 001-36201 | 23538771 | 34 | 268958 | 1 | 1 |
| 2023-01-06 | 4 | xslF345X03/e618185_4-muehler.xml | 0001193805-23-000023 | 5441 | ||||||
| 2023-01-06 | 4 | xslF345X03/e618184_4-duane.xml | 0001193805-23-000022 | 5311 | ||||||
| 2023-01-06 | 4 | xslF345X03/e618183_4-whaley.xml | 0001193805-23-000021 | 5459 | ||||||
| 2023-01-06 | 4 | xslF345X03/e618182_4-vitt.xml | 0001193805-23-000020 | 5415 | ||||||
| 2022-12-30 | 8-K | e618165_8k-immunic.htm | 1.01,9.01 | 0001193805-22-001809 | 001-36201 | 221502079 | 34 | 204875 | 1 | 1 |
| 2022-12-20 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2022-12-20 17:00:00 | 9999999995-22-003591 | 333-268737 | 221476423 | 33 | 1806 | ||
| 2022-12-20 | 424B3 | e618140_424b3-immunic.htm | 0001193805-22-001753 | 333-268737 | 221475601 | 33 | 211372 | |||
| 2022-12-16 | CORRESP | filename1.htm | 0001193805-22-001740 | 5204 | ||||||
| 2022-12-15 | UPLOAD | filename1.pdf | 0000000000-22-013534 | 40247 | ||||||
| 2022-12-15 | 4 | xslF345X03/e618126_4-jorg.xml | 0001193805-22-001729 | 7021 | ||||||
| 2022-12-09 | S-3 | e618097_s3-immunic.htm | 0001193805-22-001680 | 333-268737 | 221455338 | 33 | 304102 | |||
| 2022-11-28 | SC 13G | SC 13G | 0001193125-22-293133 | 005-88651 | 221422639 | 34 | 47846 | |||
| 2022-11-25 | 4 | xslF345X03/e618059_4-jorg.xml | 0001193805-22-001609 | 4488 | ||||||
| 2022-11-25 | SC 13G | SC 13G | 0001193125-22-292371 | 005-88651 | 221417999 | 34 | 49105 | |||
| 2022-11-25 | SC 13G | SC 13G | 0001193125-22-292368 | 005-88651 | 221417994 | 34 | 48275 | |||
| 2022-11-23 | 4 | xslF345X03/e618054_4-vitt.xml | 0001193805-22-001602 | 4972 | ||||||
| 2022-11-17 | 8-K | e618035_8k-immunic.htm | 8.01,9.01 | 0001193805-22-001568 | 001-36201 | 221396780 | 34 | 7665174 | 1 | 1 |
| 2022-11-08 | 4 | xslF345X03/e618003_4-whaley.xml | 0001193805-22-001497 | 4781 | ||||||
| 2022-11-03 | 10-Q | 10-Q | 0001280776-22-000021 | 001-36201 | 221356784 | 34 | 7725033 | 1 | 1 | |
| 2022-11-03 | 8-K | e617987_8k-immunic.htm | 2.02,8.01,9.01 | 0001193805-22-001472 | 001-36201 | 221356060 | 34 | 3784973 | 1 | 1 |
| 2022-10-24 | SC 13G | SCHEDULE 13G | 0000899140-22-000756 | 005-88651 | 221326369 | 34 | 59202 | |||
| 2022-10-21 | SC 13G | formsc13g.htm | 0001493152-22-029364 | 005-88651 | 221324384 | 34 | 104576 | |||
| 2022-10-20 | 8-K | e621964_8k-immunic.htm | 8.01,9.01 | 0001193805-22-001439 | 001-36201 | 221321492 | 34 | 221201 | 1 | 1 |
| 2022-10-20 | SC 13G | deeptrack-imux101022.htm | 0001172661-22-002221 | 005-88651 | 221321255 | 34 | 103501 | |||
| 2022-10-18 | D | xslFormDX01/primary_doc.xml | 06b | 0001193805-22-001424 | 021-462122 | 221316075 | 33 | 16364 | ||
| 2022-10-11 | 8-K | e621975_8k-immunic.htm | 1.01,3.02,7.01,9.01 | 0001193805-22-001344 | 001-36201 | 221302452 | 34 | 681304 | 1 | 1 |
| 2022-09-20 | 8-K | e621930_8k-immunic.htm | 8.01,9.01 | 0001193805-22-001285 | 001-36201 | 221252099 | 34 | 10982808 | 1 | 1 |
| 2022-08-04 | 8-K/A | e621858_8ka-immunic.htm | 8.01,9.01 | 0001193805-22-001143 | 001-36201 | 221136495 | 34 | 4942067 | 1 | 1 |
| 2022-08-04 | 10-Q | 10-Q | 0001280776-22-000017 | 001-36201 | 221134581 | 34 | 7084947 | 1 | 1 | |
| 2022-08-04 | 8-K | e621857_8k-immunic.htm | 2.02,8.01,9.01 | 0001193805-22-001141 | 001-36201 | 221134531 | 34 | 5051935 | 1 | 1 |
| 2022-07-11 | 4 | xslF345X03/e621829_4-toernsen.xml | 0001193805-22-001090 | 5433 | ||||||
| 2022-07-11 | 3 | xslF345X02/e621828_3-toernsen.xml | 0001193805-22-001089 | 2997 | ||||||
| 2022-07-08 | 8-K | e621820_8k-immunic.htm | 5.02,9.01 | 0001193805-22-001069 | 001-36201 | 221072441 | 34 | 224636 | 1 | 1 |
| 2022-06-21 | 8-K | e621762_8k-immunic.htm | 5.07 | 0001193805-22-000976 | 001-36201 | 221026193 | 34 | 196752 | 1 | 1 |
| 2022-06-17 | 4 | xslF345X03/e621761_4-duane.xml | 0001193805-22-000974 | 5435 | ||||||
| 2022-06-17 | 4 | xslF345X03/e621760_4-muehler.xml | 0001193805-22-000973 | 5439 | ||||||
| 2022-06-17 | 4 | xslF345X03/e621759_4-phillips.xml | 0001193805-22-000972 | 5295 | ||||||
| 2022-06-17 | 4 | xslF345X03/e621758_4-ossipow.xml | 0001193805-22-000971 | 5249 | ||||||
| 2022-06-17 | 4 | xslF345X03/e621757_4-jorg.xml | 0001193805-22-000970 | 5272 | ||||||
| 2022-06-17 | 4 | xslF345X03/e621756_4-whaley.xml | 0001193805-22-000969 | 5457 | ||||||
| 2022-06-17 | 4 | xslF345X03/e621755_4-vitt.xml | 0001193805-22-000968 | 5407 | ||||||
| 2022-06-17 | 4 | xslF345X03/e621754_4-howson.xml | 0001193805-22-000967 | 5149 | ||||||
| 2022-06-17 | 4 | xslF345X03/e621753_4-vdb.xml | 0001193805-22-000966 | 5287 | ||||||
| 2022-06-06 | 4 | xslF345X03/e621729_4-vitt.xml | 0001193805-22-000919 | 4970 | ||||||
| 2022-06-06 | 4 | xslF345X03/e621728_4-whaley.xml | 0001193805-22-000918 | 4546 | ||||||
| 2022-06-02 | 8-K | e621719_8k-immunic.htm | 8.01,9.01 | 0001193805-22-000895 | 001-36201 | 22989240 | 34 | 6813737 | 1 | 1 |
| 2022-05-16 | 4 | xslF345X03/e621657_4-muehler.xml | 0001193805-22-000800 | 4835 | ||||||
| 2022-05-13 | 4 | xslF345X03/e621653_4-whaley.xml | 0001193805-22-000788 | 4544 | ||||||
| 2022-05-13 | 4 | xslF345X03/e621652_4-duane.xml | 0001193805-22-000787 | 6315 | ||||||
| 2022-05-10 | 8-K | e621630_8k-immunic.htm | 2.02,7.01,9.01 | 0001193805-22-000756 | 001-36201 | 22907259 | 34 | 13253366 | 1 | 1 |
| 2022-05-10 | 10-Q | 10-Q | 0001280776-22-000012 | 001-36201 | 22907258 | 34 | 5352657 | 1 | 1 | |
| 2022-05-02 | 8-K | e621604_8k-immunic.htm | 1.01,9.01 | 0001193805-22-000711 | 001-36201 | 22879488 | 34 | 565230 | 1 | 1 |
| 2022-05-02 | 424B5 | e621601_424b5-immunic.htm | 0001193805-22-000710 | 333-250083 | 22879471 | 33 | 367414 | |||
| 2022-04-27 | DEF 14A | e621586_def14a-immunic.htm | 0001193805-22-000690 | 001-36201 | 22856405 | 34 | 358418 | |||
| 2022-04-21 | 8-K | e621584_8k-immunic.htm | 7.01 | 0001193805-22-000679 | 001-36201 | 22841455 | 34 | 198736 | 1 | 1 |
| 2022-03-16 | 8-K | e621458_8k-immunic.htm | 1.01,5.02,9.01 | 0001193805-22-000504 | 001-36201 | 22743253 | 34 | 207875 | 1 | 1 |
| 2022-03-15 | SC 13D/A | SC 13D/A | 0001193125-22-075598 | 005-88651 | 22739658 | 34 | 177225 | |||
| 2022-03-11 | 4 | xslF345X03/e621442_4-duane.xml | 0001193805-22-000473 | 5309 | ||||||
| 2022-03-11 | 4 | xslF345X03/e621441_4-whaley.xml | 0001193805-22-000472 | 5445 | ||||||
| 2022-02-24 | 10-K | 10-K | 0001280776-22-000006 | 001-36201 | 22666488 | 34 | 7507090 | 1 | 1 | |
| 2022-02-24 | 8-K | e621383_8k-immunic.htm | 2.02,8.01,9.01 | 0001193805-22-000385 | 001-36201 | 22666422 | 34 | 6895775 | 1 | 1 |
| 2022-02-18 | 8-K | e621370_8k-immunic.htm | 8.01,9.01 | 0001193805-22-000365 | 001-36201 | 22650809 | 34 | 237021 | 1 | 1 |
| 2022-02-14 | SC 13G | IMMUNIC, INC. | 0000902664-22-001585 | 005-88651 | 22625448 | 34 | 69244 | |||
| 2022-02-09 | SC 13G/A | filing.txt | 0000315066-22-001009 | 005-88651 | 22604307 | 34 | 8447 | |||
| 2022-01-10 | 8-K | e621200_8k-immunic.htm | 5.02,8.01,9.01 | 0001193805-22-000023 | 001-36201 | 22519749 | 34 | 12134794 | 1 | 1 |
| 2022-01-06 | 4 | xslF345X03/e621197_4-vitt.xml | 0001193805-22-000018 | 5416 | ||||||
| 2022-01-06 | 4 | xslF345X03/e621196_4-muehler.xml | 0001193805-22-000017 | 5442 | ||||||
| 2022-01-06 | 4 | xslF345X03/e621195_4-whaley.xml | 0001193805-22-000016 | 5445 | ||||||
| 2022-01-03 | 5 | xslF345X03/e621189_5-duane.xml | 0001193805-22-000002 | 4773 | ||||||
| 2021-12-14 | 8-K | e621156_8k-immunic.htm | 8.01,9.01 | 0001193805-21-001749 | 001-36201 | 211489742 | 34 | 19302066 | 1 | 1 |
| 2021-11-04 | 8-K | e621058_8k-immunic.htm | 2.02,8.01,9.01 | 0001193805-21-001531 | 001-36201 | 211379810 | 34 | 2808064 | 1 | 1 |
| 2021-11-04 | 10-Q | 10-Q | 0001280776-21-000023 | 001-36201 | 211377903 | 34 | 5431636 | 1 | 1 | |
| 2021-10-15 | 8-K | e621010_8k-immunic.htm | 5.02,9.01 | 0001193805-21-001455 | 001-36201 | 211326113 | 34 | 336428 | 1 | 1 |
| 2021-08-11 | 4 | xslF345X03/e620867_4-whaley.xml | 0001193805-21-001163 | 5093 | ||||||
| 2021-08-11 | 4 | xslF345X03/e620866_4-vitt.xml | 0001193805-21-001161 | 4969 | ||||||
| 2021-08-11 | 4 | xslF345X03/e620865_4-duane.xml | 0001193805-21-001159 | 4524 | ||||||
| 2021-08-06 | 8-K | e620849_8k-immunic.htm | 2.02,9.01 | 0001193805-21-001127 | 001-36201 | 211153088 | 34 | 299784 | 1 | 1 |
| 2021-08-06 | 10-Q | 10-Q | 0001280776-21-000018 | 001-36201 | 211150902 | 34 | 5401249 | 1 | 1 | |
| 2021-07-28 | S-8 | e620824_s8-immunic.htm | 0001193805-21-001075 | 333-258235 | 211123399 | 33 | 180957 | |||
| 2021-07-19 | 8-K | e620806_8k-immunic.htm | 1.01,9.01 | 0001193805-21-001043 | 001-36201 | 211098067 | 34 | 586603 | 1 | 1 |
| 2021-07-16 | 424B5 | e620800_424b5-immunic.htm | 0001193805-21-001031 | 333-250083 | 211094400 | 33 | 585352 | |||
| 2021-07-14 | 424B5 | e620798_424b5-immunic.htm | 0001193805-21-001028 | 333-250083 | 211090923 | 33 | 446046 | |||
| 2021-07-12 | 8-K | e620790_8k-immunic.htm | 8.01,9.01 | 0001193805-21-001011 | 001-36201 | 211085561 | 34 | 9658401 | 1 | 1 |
| 2021-07-12 | 8-K | e620789_8k-immunic.htm | 8.01,9.01 | 0001193805-21-001008 | 001-36201 | 211084234 | 34 | 238330 | 1 | 1 |
| 2021-07-01 | 8-K | e620764_8k-immunic.htm | 8.01,9.01 | 0001193805-21-000957 | 001-36201 | 211066024 | 34 | 7053586 | 1 | 1 |
| 2021-06-14 | 4 | xslF345X03/e620712_4-duane.xml | 0001193805-21-000874 | 5253 | ||||||
| 2021-06-14 | 4 | xslF345X03/e620713_4-ossipow.xml | 0001193805-21-000868 | 5193 | ||||||
| 2021-06-14 | 4 | xslF345X03/e620711_4-howson.xml | 0001193805-21-000867 | 5093 | ||||||
| 2021-06-14 | 4 | xslF345X03/e620710_4-phillips.xml | 0001193805-21-000866 | 5239 | ||||||
| 2021-06-14 | 4 | xslF345X03/e620709_4-jorg.xml | 0001193805-21-000865 | 5216 | ||||||
| 2021-06-14 | 4 | xslF345X03/e620708_4-vdb.xml | 0001193805-21-000864 | 5231 | ||||||
| 2021-06-14 | 8-K | e620704_8k-immunic.htm | 5.02,5.07,8.01,9.01 | 0001193805-21-000860 | 001-36201 | 211014780 | 34 | 18661255 | 1 | 1 |
| 2021-05-12 | 4 | xslF345X03/e620591_4-duane.xml | 0001193805-21-000654 | 4467 | ||||||
| 2021-05-06 | 8-K | e620558_8k-immunic.htm | 2.02,9.01 | 0001193805-21-000608 | 001-36201 | 21895904 | 34 | 280121 | 1 | 1 |
| 2021-05-06 | 10-Q | 10-Q | 0001280776-21-000013 | 001-36201 | 21895892 | 34 | 4768689 | 1 | 1 | |
| 2021-05-05 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2021-05-05 09:00:00 | 9999999995-21-001804 | 333-255303 | 21895506 | 33 | 1748 | ||
| 2021-05-03 | CORRESP | filename1.htm | 0001193805-21-000592 | 5326 | ||||||
| 2021-04-27 | DEF 14A | e620513_def14a-immunic.htm | 0001193805-21-000540 | 001-36201 | 21855886 | 34 | 553509 | |||
| 2021-04-22 | UPLOAD | filename1.pdf | 0000000000-21-005015 | 40206 | ||||||
| 2021-04-19 | 8-K | e620493_8k-immunic.htm | 1.01,5.02,9.01 | 0001193805-21-000513 | 001-36201 | 21835373 | 34 | 206375 | 1 | 1 |
| 2021-04-19 | 4 | xslF345X03/e620490_4-duane.xml | 0001193805-21-000512 | 5262 | ||||||
| 2021-04-16 | S-3 | e620479_s3-immunic.htm | 0001193805-21-000505 | 333-255303 | 21831894 | 33 | 202197 | |||
| 2021-03-31 | 8-K | e620436_8k-immunic.htm | 1.01,3.02,9.01 | 0001193805-21-000441 | 001-36201 | 21793653 | 34 | 272179 | 1 | 1 |
| 2021-03-15 | 4 | xslF345X03/e620386_4-muehler.xml | 0001193805-21-000368 | 5320 | ||||||
| 2021-03-15 | 3 | xslF345X02/e620385_3-muehler.xml | 0001193805-21-000367 | 9802 | ||||||
| 2021-03-03 | 4 | xslF345X03/e620352_4-whaley.xml | 0001193805-21-000324 | 4476 | ||||||
| 2021-03-02 | 4 | xslF345X03/e620344_4-whaley.xml | 0001193805-21-000309 | 5388 | ||||||
| 2021-03-02 | 4 | xslF345X03/e620343_4-groppel.xml | 0001193805-21-000308 | 5377 | ||||||
| 2021-03-02 | 4 | xslF345X03/e620342_4-vitt.xml | 0001193805-21-000307 | 5359 | ||||||
| 2021-02-26 | 10-K | 10-K | 0001280776-21-000009 | 001-36201 | 21683765 | 34 | 9818417 | 1 | 1 | |
| 2021-02-26 | 8-K | e620322_8k-immunic.htm | 2.02,8.01,9.01 | 0001193805-21-000273 | 001-36201 | 21683722 | 34 | 21572450 | 1 | 1 |
| 2021-02-19 | SC 13G | SC 13G | 0001193125-21-048288 | 005-88651 | 21651993 | 34 | 42946 | |||
| 2021-02-18 | 8-K | e620306_8k-immunic.htm | 8.01,9.01 | 0001193805-21-000241 | 001-36201 | 21647688 | 34 | 17133334 | 1 | 1 |
| 2021-02-16 | SC 13G/A | SC 13G/A | 0001193125-21-042148 | 005-88651 | 21631486 | 34 | 173678 | |||
| 2021-02-12 | SC 13G/A | AMENDMENT TO FORM SC 13G | 0001387131-21-002203 | 005-88651 | 21624911 | 34 | 98307 | |||
| 2021-02-08 | SC 13G | filing.txt | 0000315066-21-001064 | 005-88651 | 21599623 | 34 | 8271 | |||
| 2021-01-04 | 8-K | e620187_8k-immunic.htm | 1.01,9.01 | 0001193805-21-000002 | 001-36201 | 21500029 | 34 | 557487 | 1 | 1 |
| 2020-12-29 | 424B5 | e620183_424b5-immunic.htm | 0001193805-20-001635 | 333-250083 | 201422814 | 33 | 373418 | |||
| 2020-11-24 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2020-11-24 16:00:00 | 9999999995-20-003304 | 333-250083 | 201346739 | 33 | 1749 | ||
| 2020-11-20 | CORRESP | filename1.htm | 0001193805-20-001458 | 5140 | ||||||
| 2020-11-20 | UPLOAD | filename1.pdf | 0000000000-20-011118 | 40230 | ||||||
| 2020-11-13 | S-3 | e620079_s3-immunic.htm | 0001193805-20-001429 | 333-250083 | 201312285 | 33 | 693104 | |||
| 2020-11-13 | 8-K/A | e620080_8ka-immunic.htm | 1.01,9.01 | 0001193805-20-001425 | 001-36201 | 201311589 | 34 | 216028 | 1 | 1 |
| 2020-11-12 | 424B5 | e620073_424b5-immunic.htm | 0001193805-20-001410 | 333-225230 | 201302866 | 33 | 22873 | |||
| 2020-11-06 | 10-Q | 10-Q | 0001280776-20-000035 | 001-36201 | 201292389 | 34 | 9516543 | 1 | 1 | |
| 2020-11-05 | 8-K | e620063_8k-immunic.htm | 2.02,7.01,9.01 | 0001193805-20-001389 | 001-36201 | 201290505 | 34 | 3212679 | 1 | 1 |
| 2020-10-22 | 4 | xslF345X03/e620014_4-duane.xml | 0001193805-20-001306 | 5268 | ||||||
| 2020-10-20 | 8-K | e620006_8k-immunic.htm | 1.01,2.03,7.01,9.01 | 0001193805-20-001296 | 001-36201 | 201247332 | 34 | 1273324 | 1 | 1 |
| 2020-09-21 | SC 13D/A | e619936_sc13da-immunic.htm | 0001193805-20-001154 | 005-88651 | 201186400 | 34 | 28376 | |||
| 2020-09-11 | 8-K | e619924_8k-immunic.htm | 7.01,9.01 | 0001193805-20-001136 | 001-36201 | 201169974 | 34 | 15134390 | 1 | 1 |
| 2020-09-04 | SC 13D/A | SC 13D/A | 0001193125-20-240090 | 005-88651 | 201162031 | 34 | 57241 | |||
| 2020-08-10 | 4 | xslF345X03/e619850_4-whaley.xml | 0001193805-20-000993 | 4477 | ||||||
| 2020-08-10 | SC 13G/A | AMENDMENT TO FORM SC 13G | 0001387131-20-007254 | 005-88651 | 201088580 | 34 | 93667 | |||
| 2020-08-07 | 8-K | e619841_8k-immunic.htm | 1.01,8.01,9.01 | 0001193805-20-000975 | 001-36201 | 201086594 | 34 | 554498 | 1 | 1 |
| 2020-08-05 | 424B5 | e619835_424b5-immunic.htm | 0001193805-20-000959 | 333-225230 | 201078589 | 33 | 488545 | |||
| 2020-08-04 | 424B5 | e619827_424b5-immunic.htm | 0001193805-20-000924 | 333-225230 | 201071678 | 33 | 484348 |
One latest value per concept from companyfacts (314 concepts). Full history stays in the JSON.
| Taxonomy | Tag | Label | Unit | Value | Start | End | FY | FP | Form | Filed | Accn |
|---|---|---|---|---|---|---|---|---|---|---|---|
| dei | EntityCommonStockSharesOutstanding | Entity Common Stock, Shares Outstanding | shares | 15.88M | 2026-11-06 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| dei | EntityNumberOfEmployees | Entity Number of Employees | employee | 85 | 2024-08-01 | 2024 | Q3 | 10-Q | 2024-11-07 | 0001280776-24-000018 | |
| dei | EntityPublicFloat | Entity Public Float | USD | 83.10M | 2025-06-30 | 2025 | FY | 10-K/A | 2026-04-22 | 0001193805-26-000493 | |
| ffd | NetFeeAmt | NetFeeAmt | USD | 1,028.08 | 2026-10-01 | S-8 | 2026-10-01 | 0001193805-26-001316 | |||
| ffd | TtlFeeAmt | TtlFeeAmt | USD | 1,028.08 | 2026-10-01 | S-8 | 2026-10-01 | 0001193805-26-001316 | |||
| ffd | TtlOfferingAmt | TtlOfferingAmt | USD | 11.82M | 2026-10-01 | S-8 | 2026-10-01 | 0001193805-26-001316 | |||
| ffd | TtlOffsetAmt | TtlOffsetAmt | USD | 0 | 2026-10-01 | S-8 | 2026-10-01 | 0001193805-26-001316 | |||
| us-gaap | AccountsPayableCurrent | Accounts Payable, Current | USD | 10.12M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | AccountsPayableOtherCurrent | Accounts Payable, Other, Current | USD | 638,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | AccruedLiabilitiesCurrent | Accrued Liabilities, Current | USD | 20.06M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment | Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | USD | 9.80M | 2019-03-31 | 2019 | Q1 | 10-Q | 2019-04-10 | 0001280776-19-000032 | |
| us-gaap | AccumulatedOtherComprehensiveIncomeLossNetOfTax | Accumulated Other Comprehensive Income (Loss), Net of Tax | USD | 2.75M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | AdditionalPaidInCapital | Additional Paid in Capital | USD | 819.29M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature | USD | 28.40M | 2024-01-01 | 2024-03-31 | 2024 | Q1 | 10-Q | 2024-05-08 | 0001280776-24-000009 |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalOther | Adjustments to Additional Paid in Capital, Other | USD | 0 | 2017-01-01 | 2017-12-31 | 2018 | FY | 10-K | 2019-03-04 | 0001280776-19-000025 |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue | APIC, Share-based Payment Arrangement, Increase for Cost Recognition | USD | 13.91M | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | USD | 9,000 | 2023-07-01 | 2023-09-30 | 2023 | Q3 | 10-Q | 2023-11-14 | 0001280776-23-000018 |
| us-gaap | AllocatedShareBasedCompensationExpense | Share-based Payment Arrangement, Expense | USD | 25.16B | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares | 32.42M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable | AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable | USD | 0 | 2022-01-01 | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-03 | 0001280776-22-000021 |
| us-gaap | Assets | Assets | USD | 136.42M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | AssetsCurrent | Assets, Current | USD | 135.09M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | AssetsFairValueDisclosure | Assets, Fair Value Disclosure | USD | 93.74M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | BusinessAcquisitionsProFormaNetIncomeLoss | Business Acquisition, Pro Forma Net Income (Loss) | USD | -19.30M | 2019-01-01 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-16 | 0001280776-20-000009 |
| us-gaap | BusinessAcquisitionsProFormaRevenue | Business Acquisition, Pro Forma Revenue | USD | 0 | 2019-01-01 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-16 | 0001280776-20-000009 |
| us-gaap | CapitalExpendituresIncurredButNotYetPaid | Capital Expenditures Incurred but Not yet Paid | USD | 0 | 2019-01-01 | 2019-03-31 | 2019 | Q1 | 10-Q | 2019-04-10 | 0001280776-19-000032 |
| us-gaap | CashAndCashEquivalentsAtCarryingValue | Cash and Cash Equivalents, at Carrying Value | USD | 131.96M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | CashAndCashEquivalentsPeriodIncreaseDecrease | Cash and Cash Equivalents, Period Increase (Decrease) | USD | -3.73M | 2019-01-01 | 2019-03-31 | 2019 | Q1 | 10-Q | 2019-04-10 | 0001280776-19-000032 |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | USD | 131.96M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | USD | 116.48M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights | Class of Warrant or Right, Exercise Price of Warrants or Rights (Deprecated 2014-01-31) | USD/Warrant | 95.21 | 2014-03-31 | 2014 | Q1 | 10-Q | 2014-05-28 | 0001193125-14-215136 | |
| us-gaap | ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 | Class of Warrant or Right, Exercise Price of Warrants or Rights | USD/shares | 3,719.6 | 2019-09-25 | 2020 | FY | 10-K | 2021-02-26 | 0001280776-21-000009 | |
| us-gaap | ClassOfWarrantOrRightOutstanding | Class of Warrant or Right, Outstanding | shares | 240,620 | 2017-12-31 | 2018 | FY | 10-K | 2019-03-04 | 0001280776-19-000025 | |
| us-gaap | CommitmentsAndContingencies | Commitments and Contingencies | USD | 6.80M | 2020-03-31 | 2020 | Q1 | 10-Q | 2020-05-08 | 0001280776-20-000015 | |
| us-gaap | CommonStockCapitalSharesReservedForFutureIssuance | Common Stock, Capital Shares Reserved for Future Issuance | shares | 64.96M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | CommonStockDividendsPerShareCashPaid | Common Stock, Dividends, Per Share, Cash Paid | USD/shares | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | CommonStockDividendsPerShareDeclared | Common Stock, Dividends, Per Share, Declared | USD/shares | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | CommonStockParOrStatedValuePerShare | Common Stock, Par or Stated Value Per Share | USD/shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | CommonStockSharesAuthorized | Common Stock, Shares Authorized | shares | 500.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | CommonStockSharesIssued | Common Stock, Shares, Issued | shares | 12.04M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | CommonStockSharesOutstanding | Common Stock, Shares, Outstanding | shares | 12.04M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | CommonStockValue | Common Stock, Value, Issued | USD | 1,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | ComprehensiveIncomeNetOfTax | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | USD | -108.89M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | ContractualObligation | Contractual Obligation | USD | 1.20M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | ConversionOfStockAmountConverted1 | Conversion of Stock, Amount Converted | USD | 0 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-02-26 | 0001280776-21-000009 |
| us-gaap | ConversionOfStockSharesIssued1 | Conversion of Stock, Shares Issued | shares | 3.27M | 2003-05-23 | 2014-03-31 | 2014 | Q1 | 10-Q | 2014-05-28 | 0001193125-14-215136 |
| us-gaap | ConvertiblePreferredStockSharesIssuedUponConversion | Convertible Preferred Stock, Shares Issued upon Conversion | shares | 1 | 2014-04-30 | 2015 | Q3 | 10-Q | 2015-11-05 | 0001628280-15-008337 | |
| us-gaap | ConvertiblePreferredStockSharesReservedForFutureIssuance | Convertible Preferred Stock, Shares Reserved for Future Issuance | shares | 16.01M | 2014-03-31 | 2014 | Q1 | 10-Q | 2014-05-28 | 0001193125-14-215136 | |
| us-gaap | CostOfGoodsAndServicesSold | Cost of Goods and Services Sold | USD | 13,000 | 2003-05-23 | 2014-03-31 | 2014 | Q1 | 10-Q | 2014-05-28 | 0001193125-14-215136 |
| us-gaap | CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption | Cumulative Effect of New Accounting Principle in Period of Adoption (Deprecated 2020-01-31) | USD | 12,000 | 2019-01-01 | 2019 | Q1 | 10-Q | 2019-04-10 | 0001280776-19-000032 | |
| us-gaap | CurrentIncomeTaxExpenseBenefit | Current Income Tax Expense (Benefit) | USD | 0 | 2019-01-01 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-16 | 0001280776-20-000009 |
| us-gaap | DebtConversionConvertedInstrumentAmount1 | Debt Conversion, Converted Instrument, Amount | USD | 7.30M | 2012-01-01 | 2012-12-31 | 2014 | FY | 10-K | 2015-03-20 | 0001193125-15-098980 |
| us-gaap | DebtInstrumentConvertibleConversionPrice1 | Debt Instrument, Convertible, Conversion Price | USD/shares | 1 | 2026-04-01 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | DeferredCompensationArrangementWithIndividualCompensationExpense | Deferred Compensation Arrangement with Individual, Compensation Expense | USD | 27,000 | 2012-02-01 | 2012-02-29 | 2014 | FY | 10-K | 2015-03-20 | 0001193125-15-098980 |
| us-gaap | DeferredCompensationShareBasedArrangementsLiabilityCurrent | Deferred Compensation Share-based Arrangements, Liability, Current | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | DeferredCreditsAndOtherLiabilitiesCurrent | Deferred Credits and Other Liabilities, Current | USD | 0 | 2020-12-31 | 2020 | FY | 10-K | 2021-02-26 | 0001280776-21-000009 | |
| us-gaap | DeferredFinanceCostsCurrentNet | Debt Issuance Costs, Current, Net | USD | 3.51M | 2013-12-31 | 2014 | FY | 10-K | 2015-03-20 | 0001193125-15-098980 | |
| us-gaap | DeferredIncomeCurrent | Deferred Income, Current | USD | 0 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-06 | 0001280776-20-000035 | |
| us-gaap | DeferredIncomeTaxExpenseBenefit | Deferred Income Tax Expense (Benefit) | USD | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-31 | 0001280776-25-000005 |
| us-gaap | DeferredIncomeTaxLiabilities | Deferred Tax Liabilities, Gross | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001280776-26-000005 | |
| us-gaap | DeferredRentCreditCurrent | Deferred Rent Credit, Current | USD | 22,000 | 2018-12-31 | 2019 | Q1 | 10-Q | 2019-04-10 | 0001280776-19-000032 | |
| us-gaap | DeferredRentCreditNoncurrent | Deferred Rent Credit, Noncurrent | USD | 41,000 | 2018-12-31 | 2019 | Q1 | 10-Q | 2019-04-10 | 0001280776-19-000032 | |
| us-gaap | DeferredTaxAssetsGoodwillAndIntangibleAssets | Deferred Tax Assets, Goodwill and Intangible Assets | USD | 2.09M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001280776-26-000005 | |
| us-gaap | DeferredTaxAssetsGross | Deferred Tax Assets, Gross | USD | 119.87M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001280776-26-000005 | |
| us-gaap | DeferredTaxAssetsLiabilitiesNet | Deferred Tax Assets, Net | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001280776-26-000005 | |
| us-gaap | DeferredTaxAssetsNet | Deferred Tax Assets, Net of Valuation Allowance | USD | 0 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-16 | 0001280776-20-000009 | |
| us-gaap | DeferredTaxAssetsOperatingLossCarryforwardsForeign | Deferred Tax Assets, Operating Loss Carryforwards, Foreign | USD | 90.64M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001280776-26-000005 | |
| us-gaap | DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal | Deferred Tax Assets, Operating Loss Carryforwards, State and Local | USD | 24.48M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001280776-26-000005 | |
| us-gaap | DeferredTaxAssetsOther | Deferred Tax Assets, Other | USD | 207,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001280776-26-000005 | |
| us-gaap | DeferredTaxAssetsTaxCreditCarryforwards | Deferred Tax Assets, Tax Credit Carryforwards | USD | 0 | 2020-12-31 | 2020 | FY | 10-K | 2021-02-26 | 0001280776-21-000009 | |
| us-gaap | DeferredTaxAssetsTaxCreditCarryforwardsResearch | Deferred Tax Assets, Tax Credit Carryforwards, Research | USD | 6.06M | 2016-12-31 | 2016 | FY | 10-K | 2017-03-07 | 0001280776-17-000010 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | USD | 2.45M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001280776-26-000005 | |
| us-gaap | DeferredTaxAssetsUnrealizedCurrencyLosses | Deferred Tax Assets, Unrealized Currency Losses | USD | 0 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-31 | 0001280776-25-000005 | |
| us-gaap | DeferredTaxAssetsValuationAllowance | Deferred Tax Assets, Valuation Allowance | USD | 119.87M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001280776-26-000005 | |
| us-gaap | DeferredTaxLiabilitiesPropertyPlantAndEquipment | Deferred Tax Liabilities, Property, Plant and Equipment | USD | 0 | 2022-12-31 | 2022 | FY | 10-K | 2023-02-23 | 0001280776-23-000004 | |
| us-gaap | Depreciation | Depreciation | USD | 99,000 | 2024-01-01 | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-07 | 0001280776-24-000018 |
| us-gaap | DepreciationAndAmortization | Depreciation, Depletion and Amortization, Nonproduction | USD | 105,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | DepreciationDepletionAndAmortization | Depreciation, Depletion and Amortization | USD | 105,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage | Development Stage Enterprise, Deficit Accumulated During Development Stage (Deprecated 2015-01-31) | USD | 113.91M | 2014-03-31 | 2014 | Q1 | 10-Q | 2014-05-28 | 0001193125-14-215136 | |
| us-gaap | DirectCostsOfLeasedAndRentedPropertyOrEquipment | Direct Costs of Leased and Rented Property or Equipment | USD | 999,000 | 2017-01-01 | 2017-12-31 | 2017 | FY | 10-K | 2018-03-13 | 0001280776-18-000013 |
| us-gaap | EarningsPerShareBasic | Earnings Per Share, Basic | USD/shares | -2.83 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | EarningsPerShareBasicAndDiluted | Earnings Per Share, Basic and Diluted | USD/shares | -3.33 | 2021-01-01 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-04 | 0001280776-21-000023 |
| us-gaap | EarningsPerShareDiluted | Earnings Per Share, Diluted | USD/shares | -2.83 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | EffectiveIncomeTaxRateContinuingOperations | Effective Income Tax Rate Reconciliation, Percent | pure | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001280776-26-000005 |
| us-gaap | EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | pure | 0.21 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001280776-26-000005 |
| us-gaap | EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent | pure | -0.176 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001280776-26-000005 |
| us-gaap | EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate | Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent | pure | 0 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-02-22 | 0001280776-24-000004 |
| us-gaap | EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential | Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent | pure | 0.028 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001280776-26-000005 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent | pure | 0 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-02-22 | 0001280776-24-000004 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent | pure | -0.002 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001280776-26-000005 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent | pure | 0.038 | 2014-01-01 | 2014-12-31 | 2014 | FY | 10-K | 2015-03-20 | 0001193125-15-098980 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent | pure | -0.014 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001280776-26-000005 |
| us-gaap | EffectiveIncomeTaxRateReconciliationOtherAdjustments | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent | pure | 0 | 2016-01-01 | 2016-12-31 | 2016 | FY | 10-K | 2017-03-07 | 0001280776-17-000010 |
| us-gaap | EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent | Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent | pure | -0.009 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001280776-26-000005 |
| us-gaap | EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings | Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent | pure | -0.004 | 2014-01-01 | 2014-12-31 | 2014 | FY | 10-K | 2015-03-20 | 0001193125-15-098980 |
| us-gaap | EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent | pure | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001280776-26-000005 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxContingencies | Effective Income Tax Rate Reconciliation, Tax Contingency, Percent | pure | 0 | 2018-01-01 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-04 | 0001280776-19-000025 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxCredits | Effective Income Tax Rate Reconciliation, Tax Credit, Percent | pure | -0.002 | 2018-01-01 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-04 | 0001280776-19-000025 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxCreditsOther | Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent | pure | 0 | 2015-01-01 | 2015-12-31 | 2015 | FY | 10-K | 2016-03-08 | 0001628280-16-012388 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxCreditsResearch | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent | pure | -0.029 | 2016-01-01 | 2016-12-31 | 2016 | FY | 10-K | 2017-03-07 | 0001280776-17-000010 |
| us-gaap | EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations | Effect of Exchange Rate on Cash and Cash Equivalents, Continuing Operations | USD | -1,000 | 2018-01-01 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-04 | 0001280776-19-000025 |
| us-gaap | EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | USD | -553,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | EmployeeRelatedLiabilitiesCurrent | Employee-related Liabilities, Current | USD | 335,000 | 2019-09-30 | 2019 | Q3 | 10-Q | 2019-11-07 | 0001280776-19-000056 | |
| us-gaap | EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized | Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | USD | 11.00M | 2023-12-31 | 2023 | FY | 10-K | 2024-02-22 | 0001280776-24-000004 | |
| us-gaap | EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | USD | 900,000 | 2024-03-31 | 2024 | Q1 | 10-Q | 2024-05-08 | 0001280776-24-000009 | |
| us-gaap | FairValueAssumptionsExercisePrice | Fair Value Assumptions, Exercise Price (Deprecated 2018-01-31) | USD | 8 | 2013-12-01 | 2015 | FY | 10-K | 2016-03-08 | 0001628280-16-012388 | |
| us-gaap | FairValueAssumptionsExpectedDividendRate | Fair Value Assumptions, Expected Dividend Rate (Deprecated 2018-01-31) | pure | 0 | 2018-01-01 | 2018-06-30 | 2018 | Q2 | 10-Q | 2018-08-07 | 0001280776-18-000079 |
| us-gaap | FairValueAssumptionsExpectedVolatilityRate | Fair Value Assumptions, Expected Volatility Rate (Deprecated 2018-01-31) | pure | 0.85 | 2013-01-01 | 2013-12-31 | 2015 | FY | 10-K | 2016-03-08 | 0001628280-16-012388 |
| us-gaap | FairValueAssumptionsRiskFreeInterestRate | Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) | pure | 0.004 | 2013-01-01 | 2013-12-31 | 2015 | FY | 10-K | 2016-03-08 | 0001628280-16-012388 |
| us-gaap | FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings | USD | 23.60M | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001280776-26-000005 |
| us-gaap | FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) | USD | 4.80M | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001280776-26-000005 |
| us-gaap | FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value | USD | 0 | 2024-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001280776-26-000005 | |
| us-gaap | ForeignCurrencyTransactionGainLossBeforeTax | Foreign Currency Transaction Gain (Loss), before Tax | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001280776-26-000005 |
| us-gaap | ForeignCurrencyTransactionGainLossUnrealized | Foreign Currency Transaction Gain (Loss), Unrealized | USD | 0 | 2025-01-01 | 2025-09-30 | 2025 | Q3 | 10-Q | 2025-11-13 | 0001280776-25-000017 |
| us-gaap | GainLossOnSaleOfEquityInvestments | Gain (Loss) on Sale of Equity Investments | USD | 0 | 2020-01-01 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-06 | 0001280776-20-000035 |
| us-gaap | GainLossOnSaleOfInvestments | Gain (Loss) on Sale of Investments | USD | 0 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-02-26 | 0001280776-21-000009 |
| us-gaap | GainLossOnSaleOfPropertyPlantEquipment | Gain (Loss) on Disposition of Property Plant Equipment | USD | 0 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-02-26 | 0001280776-21-000009 |
| us-gaap | GeneralAndAdministrativeExpense | General and Administrative Expense | USD | 36.43M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | Goodwill | Goodwill | USD | 0 | 2022-12-31 | 2022 | FY | 10-K | 2023-02-23 | 0001280776-23-000004 | |
| us-gaap | GoodwillImpairmentLoss | Goodwill, Impairment Loss | USD | 0 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-02-22 | 0001280776-24-000004 |
| us-gaap | GovernmentAssistanceAmount | GovernmentAssistanceAmount | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | GovernmentAssistanceExpense | GovernmentAssistanceExpense | USD | 7,000 | 2025-04-01 | 2025-06-30 | 2025 | Q2 | 10-Q | 2025-08-07 | 0001280776-25-000012 |
| us-gaap | GrossProfit | Gross Profit | USD | 9,000 | 2003-05-23 | 2014-03-31 | 2014 | Q1 | 10-Q | 2014-05-28 | 0001193125-14-215136 |
| us-gaap | ImpairmentOfLongLivedAssetsHeldForUse | Impairment of Long-Lived Assets Held-for-use | USD | 1.22M | 2018-01-01 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-04 | 0001280776-19-000025 |
| us-gaap | IncomeLossAttributableToParent | Income (Loss) Attributable to Parent, before Tax | USD | -97.17M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001280776-26-000005 |
| us-gaap | IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple | Income (Loss) from Operations before Extraordinary Items (Deprecated 2019-01-31) | USD | -113.92M | 2003-05-23 | 2014-03-31 | 2014 | Q1 | 10-Q | 2014-05-28 | 0001193125-14-215136 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic | Income (Loss) from Continuing Operations before Income Taxes, Domestic | USD | -41.47M | 2018-01-01 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-04 | 0001280776-19-000025 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | USD | -41.48M | 2018-01-01 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-04 | 0001280776-19-000025 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign | Income (Loss) from Continuing Operations before Income Taxes, Foreign | USD | -8,000 | 2018-01-01 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-04 | 0001280776-19-000025 |
| us-gaap | IncomeTaxExpenseBenefit | Income Tax Expense (Benefit) | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001280776-26-000005 |
| us-gaap | IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount | USD | -20.41M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001280776-26-000005 |
| us-gaap | IncomeTaxReconciliationNondeductibleExpenseOther | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount | USD | 196,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001280776-26-000005 |
| us-gaap | IncreaseDecreaseInAccountsPayable | Increase (Decrease) in Accounts Payable | USD | 315,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | IncreaseDecreaseInAccruedLiabilities | Increase (Decrease) in Accrued Liabilities | USD | 1.87M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | IncreaseDecreaseInDerivativeLiabilities | Increase (Decrease) in Derivative Liabilities | USD | 4,796 | 2024-01-01 | 2024-03-31 | 2024 | Q3 | 10-Q | 2024-11-07 | 0001280776-24-000018 |
| us-gaap | IncreaseDecreaseInOperatingLeaseLiability | IncreaseDecreaseInOperatingLeaseLiability | USD | -419,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | IncreaseDecreaseInOtherCurrentLiabilities | Increase (Decrease) in Other Current Liabilities | USD | 5.96M | 2023-01-01 | 2023-09-30 | 2023 | Q3 | 10-Q | 2023-11-14 | 0001280776-23-000018 |
| us-gaap | IncreaseDecreaseInOtherOperatingLiabilities | Increase (Decrease) in Other Operating Liabilities | USD | 745,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets | Increase (Decrease) in Prepaid Expense and Other Assets | USD | -4.12M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | IncreaseDecreaseInRestrictedCash | Increase (Decrease) in Restricted Cash | USD | 75,000 | 2019-01-01 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-16 | 0001280776-20-000009 |
| us-gaap | IncrementalCommonSharesAttributableToShareBasedPaymentArrangements | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements | shares | 1.34M | 2019-01-01 | 2019-03-31 | 2019 | Q1 | 10-Q | 2019-04-10 | 0001280776-19-000032 |
| us-gaap | InterestExpense | Interest Expense | USD | 413,000 | 2012-01-01 | 2012-12-31 | 2014 | FY | 10-K | 2015-03-20 | 0001193125-15-098980 |
| us-gaap | InterestPaid | Interest Paid, Including Capitalized Interest, Operating and Investing Activities | USD | 32,000 | 2012-01-01 | 2012-12-31 | 2014 | FY | 10-K | 2015-03-20 | 0001193125-15-098980 |
| us-gaap | InterestPaidNet | Interest Paid, Excluding Capitalized Interest, Operating Activities | USD | 0 | 2020-01-01 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-06 | 0001280776-20-000035 |
| us-gaap | InvestmentIncomeInterest | Investment Income, Interest | USD | 3.14M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | InvestmentIncomeInvestmentExpense | Investment Income, Investment Expense | USD | 1,000 | 2018-01-01 | 2018-12-31 | 2019 | FY | 10-K | 2020-03-16 | 0001280776-20-000009 |
| us-gaap | IssuanceOfStockAndWarrantsForServicesOrClaims | Issuance of Stock and Warrants for Services or Claims | USD | 0 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-02-23 | 0001280776-23-000004 |
| us-gaap | LeaseholdImprovementsGross | Leasehold Improvements, Gross | USD | 478,000 | 2013-12-31 | 2014 | FY | 10-K | 2015-03-20 | 0001193125-15-098980 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDue | Lessee, Operating Lease, Liability, to be Paid | USD | 544,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive | Lessee, Operating Lease, Liability, to be Paid, after Year Five | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001280776-26-000005 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths | Lessee, Operating Lease, Liability, to be Paid, Year One | USD | 279,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearFive | Lessee, Operating Lease, Liability, to be Paid, Year Five | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001280776-26-000005 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearFour | Lessee, Operating Lease, Liability, to be Paid, Year Four | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearThree | Lessee, Operating Lease, Liability, to be Paid, Year Three | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearTwo | Lessee, Operating Lease, Liability, to be Paid, Year Two | USD | 197,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear | Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year | USD | 68,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | LesseeOperatingLeaseLiabilityUndiscountedExcessAmount | Lessee, Operating Lease, Liability, Undiscounted Excess Amount | USD | 41,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | Liabilities | Liabilities | USD | 31.95M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | LiabilitiesAndStockholdersEquity | Liabilities and Equity | USD | 136.42M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | LiabilitiesCurrent | Liabilities, Current | USD | 31.55M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | LiabilitiesFairValueDisclosure | Financial and Nonfinancial Liabilities, Fair Value Disclosure | USD | 809,000 | 2025-12-31 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | LiabilitiesFairValueDisclosureRecurring | Liabilities, Fair Value Disclosure, Recurring (Deprecated 2018-01-31) | USD | 0 | 2017-12-31 | 2017 | FY | 10-K | 2018-03-13 | 0001280776-18-000013 | |
| us-gaap | LiabilitiesNoncurrent | Liabilities, Noncurrent | USD | 400,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | ManagementFeeExpense | Management Fee Expense | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001280776-26-000005 |
| us-gaap | NetCashProvidedByUsedInFinancingActivities | Net Cash Provided by (Used in) Financing Activities | USD | 194.08M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | NetCashProvidedByUsedInFinancingActivitiesContinuingOperations | Net Cash Provided by (Used in) Financing Activities, Continuing Operations | USD | 29.96M | 2019-01-01 | 2019-06-30 | 2019 | Q2 | 10-Q | 2019-08-08 | 0001280776-19-000051 |
| us-gaap | NetCashProvidedByUsedInInvestingActivities | Net Cash Provided by (Used in) Investing Activities | USD | -355,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | NetCashProvidedByUsedInInvestingActivitiesContinuingOperations | Net Cash Provided by (Used in) Investing Activities, Continuing Operations | USD | 9.32M | 2019-01-01 | 2019-06-30 | 2019 | Q2 | 10-Q | 2019-08-08 | 0001280776-19-000051 |
| us-gaap | NetCashProvidedByUsedInOperatingActivities | Net Cash Provided by (Used in) Operating Activities | USD | -76.69M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | NetCashProvidedByUsedInOperatingActivitiesContinuingOperations | Net Cash Provided by (Used in) Operating Activities, Continuing Operations | USD | -16.30M | 2019-01-01 | 2019-06-30 | 2019 | Q2 | 10-Q | 2019-08-08 | 0001280776-19-000051 |
| us-gaap | NetIncomeLoss | Net Income (Loss) Attributable to Parent | USD | -109.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | NetIncomeLossAvailableToCommonStockholdersBasic | Net Income (Loss) Available to Common Stockholders, Basic | USD | -52.08M | 2017-01-01 | 2017-12-31 | 2017 | FY | 10-K | 2018-03-13 | 0001280776-18-000013 |
| us-gaap | NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnNetIncome | New Accounting Pronouncement or Change in Accounting Principle, Effect of Change on Net Income (Deprecated 2020-01-31) | USD | 5,000 | 2003-05-23 | 2014-03-31 | 2014 | Q1 | 10-Q | 2014-05-28 | 0001193125-14-215136 |
| us-gaap | NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1 | Noncash or Part Noncash Acquisition, Value of Assets Acquired | USD | 0 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-02-26 | 0001280776-21-000009 |
| us-gaap | NonoperatingIncomeExpense | Nonoperating Income (Expense) | USD | 2.94M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | NotesAndLoansReceivableNetCurrent | Financing Receivable, after Allowance for Credit Loss, Current | USD | 920,000 | 2019-06-30 | 2019 | Q2 | 10-Q | 2019-08-08 | 0001280776-19-000051 | |
| us-gaap | NumberOfReportableSegments | Number of Reportable Segments | segment | 1 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | OperatingExpenses | Operating Expenses | USD | 111.93M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | OperatingIncomeLoss | Operating Income (Loss) | USD | -111.93M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | OperatingLeaseExpense | Operating Lease, Expense | USD | 1.12M | 2018-01-01 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-04 | 0001280776-19-000025 |
| us-gaap | OperatingLeaseLiability | Operating Lease, Liability | USD | 503,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | OperatingLeaseLiabilityCurrent | Operating Lease, Liability, Current | USD | 246,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | OperatingLeaseLiabilityNoncurrent | Operating Lease, Liability, Noncurrent | USD | 328,000 | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-08-11 | 0001280776-26-000018 | |
| us-gaap | OperatingLeaseRightOfUseAsset | Operating Lease, Right-of-Use Asset | USD | 504,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDue | Operating Leases, Future Minimum Payments Due | USD | 2.58M | 2017-12-31 | 2017 | FY | 10-K | 2018-03-13 | 0001280776-18-000013 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueCurrent | Operating Leases, Future Minimum Payments Due, Next Twelve Months | USD | 1.07M | 2017-12-31 | 2017 | FY | 10-K | 2018-03-13 | 0001280776-18-000013 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInFiveYears | Operating Leases, Future Minimum Payments, Due in Five Years | USD | 221,000 | 2017-12-31 | 2017 | FY | 10-K | 2018-03-13 | 0001280776-18-000013 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInFourYears | Operating Leases, Future Minimum Payments, Due in Four Years | USD | 434,000 | 2017-12-31 | 2017 | FY | 10-K | 2018-03-13 | 0001280776-18-000013 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInThreeYears | Operating Leases, Future Minimum Payments, Due in Three Years | USD | 387,000 | 2017-12-31 | 2017 | FY | 10-K | 2018-03-13 | 0001280776-18-000013 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInTwoYears | Operating Leases, Future Minimum Payments, Due in Two Years | USD | 469,000 | 2017-12-31 | 2017 | FY | 10-K | 2018-03-13 | 0001280776-18-000013 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueThereafter | Operating Leases, Future Minimum Payments, Due Thereafter | USD | 0 | 2017-12-31 | 2017 | FY | 10-K | 2018-03-13 | 0001280776-18-000013 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear | Operating Leases, Future Minimum Payments, Remainder of Fiscal Year | USD | 223,000 | 2017-09-30 | 2017 | Q3 | 10-Q | 2017-10-25 | 0001280776-17-000098 | |
| us-gaap | OperatingLeasesRentExpenseNet | Operating Leases, Rent Expense, Net | USD | 149,000 | 2019-01-01 | 2019-03-31 | 2019 | Q1 | 10-Q | 2019-04-10 | 0001280776-19-000032 |
| us-gaap | OtherAccruedLiabilitiesCurrent | Other Accrued Liabilities, Current | USD | 1.53M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | OtherAssetsCurrent | Other Assets, Current | USD | 842,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | OtherAssetsNoncurrent | Other Assets, Noncurrent | USD | 0 | 2023-12-31 | 2023 | FY | 10-K | 2024-02-22 | 0001280776-24-000004 | |
| us-gaap | OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent | Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent | USD | 0 | 2019-01-01 | 2019-03-31 | 2019 | Q1 | 10-Q | 2019-04-10 | 0001280776-19-000032 |
| us-gaap | OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent | USD | 101,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | OtherComprehensiveIncomeLossNetOfTax | Other Comprehensive Income (Loss), Net of Tax | USD | 776,000 | 2023-01-01 | 2023-03-31 | 2024 | Q1 | 10-Q | 2024-05-08 | 0001280776-24-000009 |
| us-gaap | OtherDeferredCreditsCurrent | Other Deferred Credits, Current | USD | 663,000 | 2020-03-31 | 2020 | Q1 | 10-Q | 2020-05-08 | 0001280776-20-000015 | |
| us-gaap | OtherLiabilitiesCurrent | Other Liabilities, Current | USD | 1.37M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | OtherLiabilitiesNoncurrent | Other Liabilities, Noncurrent | USD | 400,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | OtherNoncashIncomeExpense | Other Noncash Income (Expense) | USD | -119,000 | 2018-01-01 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-04 | 0001280776-19-000025 |
| us-gaap | OtherNonoperatingIncomeExpense | Other Nonoperating Income (Expense) | USD | -204,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | OtherOperatingActivitiesCashFlowStatement | Other Operating Activities, Cash Flow Statement | USD | 0 | 2019-01-01 | 2019-03-31 | 2019 | Q1 | 10-Q | 2019-04-10 | 0001280776-19-000032 |
| us-gaap | OtherShortTermInvestments | Other Short-term Investments | USD | 0 | 2023-12-31 | 2023 | FY | 10-K | 2024-02-22 | 0001280776-24-000004 | |
| us-gaap | OtherSundryLiabilitiesCurrent | Other Sundry Liabilities, Current | USD | 1.13M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | PaidInKindInterest | Paid-in-Kind Interest | USD | 382,000 | 2012-01-01 | 2012-12-31 | 2014 | FY | 10-K | 2015-03-20 | 0001193125-15-098980 |
| us-gaap | PaymentsForCommissions | Payments for Commissions | USD | 0 | 2017-01-01 | 2017-12-31 | 2018 | FY | 10-K | 2019-03-04 | 0001280776-19-000025 |
| us-gaap | PaymentsForProceedsFromInvestments | Payments for (Proceeds from) Investments | USD | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-31 | 0001280776-25-000005 |
| us-gaap | PaymentsOfDebtIssuanceCosts | Payments of Debt Issuance Costs | USD | 0 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-02-26 | 0001280776-21-000009 |
| us-gaap | PaymentsOfFinancingCosts | Payments of Financing Costs | USD | 0 | 2019-01-01 | 2019-03-31 | 2019 | Q1 | 10-Q | 2019-04-10 | 0001280776-19-000032 |
| us-gaap | PaymentsOfStockIssuanceCosts | Payments of Stock Issuance Costs | USD | 9,000 | 2023-01-01 | 2023-09-30 | 2023 | Q3 | 10-Q | 2023-11-14 | 0001280776-23-000018 |
| us-gaap | PaymentsToAcquireIntangibleAssets | Payments to Acquire Intangible Assets | USD | 0 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-02-26 | 0001280776-21-000009 |
| us-gaap | PaymentsToAcquireOtherInvestments | Payments to Acquire Other Investments | USD | 9.63M | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-02-23 | 0001280776-23-000004 |
| us-gaap | PaymentsToAcquireProductiveAssets | Payments to Acquire Productive Assets | USD | 75,000 | 2019-01-01 | 2019-09-30 | 2019 | Q3 | 10-Q | 2019-11-07 | 0001280776-19-000056 |
| us-gaap | PaymentsToAcquirePropertyPlantAndEquipment | Payments to Acquire Property, Plant, and Equipment | USD | 355,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | PaymentsToAcquireShortTermInvestments | Payments to Acquire Short-term Investments | USD | 0 | 2015-01-01 | 2015-12-31 | 2015 | FY | 10-K | 2016-03-08 | 0001628280-16-012388 |
| us-gaap | PreferredStockParOrStatedValuePerShare | Preferred Stock, Par or Stated Value Per Share | USD/shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | PreferredStockSharesAuthorized | Preferred Stock, Shares Authorized | shares | 20.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | PreferredStockSharesIssued | Preferred Stock, Shares Issued | shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | PreferredStockSharesOutstanding | Preferred Stock, Shares Outstanding | shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | PreferredStockValue | Preferred Stock, Value, Issued | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | PrepaidExpenseAndOtherAssetsCurrent | Prepaid Expense and Other Assets, Current | USD | 3.12M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | PrepaidInsurance | Prepaid Insurance | USD | 671,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | ProceedsFromDebtNetOfIssuanceCosts | Proceeds from Debt, Net of Issuance Costs | USD | 0 | 2025-01-01 | 2025-03-31 | 2025 | Q1 | 10-Q | 2025-05-15 | 0001280776-25-000008 |
| us-gaap | ProceedsFromIssuanceInitialPublicOffering | Proceeds from Issuance Initial Public Offering | USD | 0 | 2021-01-01 | 2021-03-31 | 2021 | Q1 | 10-Q | 2021-05-06 | 0001280776-21-000013 |
| us-gaap | ProceedsFromIssuanceOfCommonStock | Proceeds from Issuance of Common Stock | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001280776-26-000005 |
| us-gaap | ProceedsFromIssuanceOfConvertiblePreferredStock | Proceeds from Issuance of Convertible Preferred Stock | USD | 0 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-02-26 | 0001280776-21-000009 |
| us-gaap | ProceedsFromIssuanceOfPreferredStockAndPreferenceStock | Proceeds from Issuance of Preferred Stock and Preference Stock | USD | 0 | 2020-01-01 | 2020-03-31 | 2020 | Q1 | 10-Q | 2020-05-08 | 0001280776-20-000015 |
| us-gaap | ProceedsFromIssuanceOfPrivatePlacement | Proceeds from Issuance of Private Placement | USD | 690.00M | 2019-04-15 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised | USD | 86,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | ProceedsFromSaleOfMachineryAndEquipment | Proceeds from Sale of Machinery and Equipment | USD | 0 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-02-26 | 0001280776-21-000009 |
| us-gaap | ProceedsFromSaleOfOtherInvestments | Proceeds from Sale of Other Investments | USD | 9.80M | 2023-01-01 | 2023-06-30 | 2023 | Q2 | 10-Q | 2023-08-03 | 0001280776-23-000013 |
| us-gaap | ProceedsFromSaleOfOtherPropertyPlantAndEquipment | Proceeds from Sale of Other Property, Plant, and Equipment | USD | 0 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-02-26 | 0001280776-21-000009 |
| us-gaap | ProceedsFromSaleOfProductiveAssets | Proceeds from Sale of Productive Assets | USD | 9.80M | 2023-01-01 | 2023-09-30 | 2023 | Q3 | 10-Q | 2023-11-14 | 0001280776-23-000018 |
| us-gaap | ProceedsFromSaleOfShortTermInvestments | Proceeds from Sale of Short-term Investments | USD | 0 | 2015-01-01 | 2015-12-31 | 2015 | FY | 10-K | 2016-03-08 | 0001628280-16-012388 |
| us-gaap | ProceedsFromStockOptionsExercised | Proceeds from Stock Options Exercised | USD | 321,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | ProceedsFromWarrantExercises | Proceeds from Warrant Exercises | USD | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-31 | 0001280776-25-000005 |
| us-gaap | ProfitLoss | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | USD | -52.08M | 2017-01-01 | 2017-12-31 | 2017 | FY | 10-K | 2018-03-13 | 0001280776-18-000013 |
| us-gaap | PropertyPlantAndEquipmentGross | Property, Plant and Equipment, Gross | USD | 10.28M | 2019-03-31 | 2019 | Q1 | 10-Q | 2019-04-10 | 0001280776-19-000032 | |
| us-gaap | PropertyPlantAndEquipmentNet | Property, Plant and Equipment, Net | USD | 832,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | ProvisionForLoanLeaseAndOtherLosses | Provision for Loan, Lease, and Other Losses | USD | 416,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | PurchaseObligation | Purchase Obligation | USD | 431,000 | 2017-12-31 | 2017 | FY | 10-K | 2018-03-13 | 0001280776-18-000013 | |
| us-gaap | PurchaseObligationDueAfterFifthYear | Purchase Obligation, to be Paid, after Year Five | USD | 0 | 2017-12-31 | 2017 | FY | 10-K | 2018-03-13 | 0001280776-18-000013 | |
| us-gaap | PurchaseObligationDueInFourthAndFifthYear | Purchase Obligation, to be Paid, Year Four and Five | USD | 0 | 2017-12-31 | 2017 | FY | 10-K | 2018-03-13 | 0001280776-18-000013 | |
| us-gaap | PurchaseObligationDueInNextTwelveMonths | Purchase Obligation, to be Paid, Year One | USD | 431,000 | 2017-12-31 | 2017 | FY | 10-K | 2018-03-13 | 0001280776-18-000013 | |
| us-gaap | PurchaseObligationDueInSecondAndThirdYear | Purchase Obligation, to be Paid, Year Two and Three | USD | 0 | 2017-12-31 | 2017 | FY | 10-K | 2018-03-13 | 0001280776-18-000013 | |
| us-gaap | RelatedPartyTransactionAmountsOfTransaction | Related Party Transaction, Amounts of Transaction | USD | 72,000 | 2019-05-01 | 2019-05-31 | 2019 | Q2 | 10-Q | 2019-08-08 | 0001280776-19-000051 |
| us-gaap | RepaymentsOfLongTermDebt | Repayments of Long-term Debt | USD | 533,000 | 2012-01-01 | 2012-12-31 | 2014 | FY | 10-K | 2015-03-20 | 0001193125-15-098980 |
| us-gaap | ResearchAndDevelopmentExpense | Research and Development Expense | USD | 75.50M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | RestrictedCash | Restricted Cash | EUR | 18.20M | 2019-03-31 | 2020 | Q1 | 10-Q | 2020-05-08 | 0001280776-20-000015 | |
| us-gaap | RestrictedCashAndCashEquivalents | Restricted Cash and Cash Equivalents | USD | 0 | 2020-03-31 | 2020 | Q1 | 10-Q | 2020-05-08 | 0001280776-20-000015 | |
| us-gaap | RestrictedCashAndCashEquivalentsAtCarryingValue | Restricted Cash and Cash Equivalents, Current | USD | 0 | 2016-12-31 | 2016 | FY | 10-K | 2017-03-07 | 0001280776-17-000010 | |
| us-gaap | RetainedEarningsAccumulatedDeficit | Retained Earnings (Accumulated Deficit) | USD | -717.57M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | USD | 345,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | SalesRevenueNet | Revenue, Net (Deprecated 2018-01-31) | USD | 22,000 | 2003-05-23 | 2014-03-31 | 2014 | Q1 | 10-Q | 2014-05-28 | 0001193125-14-215136 |
| us-gaap | SeveranceCosts1 | Severance Costs | USD | 6.37M | 2019-01-01 | 2019-03-31 | 2019 | Q1 | 10-Q | 2019-04-10 | 0001280776-19-000032 |
| us-gaap | ShareBasedCompensation | Share-based Payment Arrangement, Noncash Expense | USD | 25.16M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost | Share-based Payment Arrangement, Accelerated Cost | USD | 1.20M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001280776-26-000005 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate | Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date | pure | 0.06 | 2013-09-30 | 2015 | FY | 10-K | 2016-03-08 | 0001628280-16-012388 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value | USD/shares | 0.25 | 2018-01-01 | 2018-03-31 | 2019 | Q1 | 10-Q | 2019-04-10 | 0001280776-19-000032 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | pure | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum | pure | 1.15 | 2026-01-01 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-13 | 0001280776-26-000010 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum | pure | 0.8 | 2026-01-01 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-13 | 0001280776-26-000010 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum | pure | 0.042 | 2026-01-01 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-13 | 0001280776-26-000010 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum | pure | 0.038 | 2026-01-01 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-13 | 0001280776-26-000010 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate | pure | 0.81 | 2014-01-01 | 2014-03-31 | 2014 | Q1 | 10-Q | 2014-05-28 | 0001193125-14-215136 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant | Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | shares | 163,627 | 2016-09-30 | 2016 | Q3 | 10-Q | 2016-11-03 | 0001280776-16-000026 | |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | USD | 0 | 2019-03-31 | 2019 | Q1 | 10-Q | 2019-04-10 | 0001280776-19-000032 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | shares | 500,000 | 2025-07-07 | 2026 | Q1 | 10-Q | 2026-05-13 | 0001280776-26-000010 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | USD/shares | 7.17 | 2019-03-31 | 2019 | Q1 | 10-Q | 2019-04-10 | 0001280776-19-000032 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | USD | 2,000 | 2018-01-01 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-04 | 0001280776-19-000025 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period | shares | 4.69M | 2019-01-01 | 2019-03-31 | 2019 | Q1 | 10-Q | 2019-04-10 | 0001280776-19-000032 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price | USD/shares | 6.33 | 2019-01-01 | 2019-03-31 | 2019 | Q1 | 10-Q | 2019-04-10 | 0001280776-19-000032 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period | shares | 27,230 | 2012-02-01 | 2012-02-29 | 2014 | FY | 10-K | 2015-03-20 | 0001193125-15-098980 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures | shares | 35,408 | 2017-01-01 | 2017-03-31 | 2017 | Q1 | 10-Q | 2017-05-09 | 0001280776-17-000029 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares | 0 | 2019-01-01 | 2019-03-31 | 2019 | Q1 | 10-Q | 2019-04-10 | 0001280776-19-000032 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | USD/shares | 4.4 | 2018-01-01 | 2018-03-31 | 2019 | Q1 | 10-Q | 2019-04-10 | 0001280776-19-000032 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | USD | 0 | 2019-03-31 | 2019 | Q1 | 10-Q | 2019-04-10 | 0001280776-19-000032 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | shares | 1.49M | 2019-03-31 | 2019 | Q1 | 10-Q | 2019-04-10 | 0001280776-19-000032 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | USD/shares | 7.08 | 2019-03-31 | 2019 | Q1 | 10-Q | 2019-04-10 | 0001280776-19-000032 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value | USD | 0 | 2019-03-31 | 2019 | Q1 | 10-Q | 2019-04-10 | 0001280776-19-000032 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | shares | 1.48M | 2019-03-31 | 2019 | Q1 | 10-Q | 2019-04-10 | 0001280776-19-000032 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | USD/shares | 7.09 | 2019-03-31 | 2019 | Q1 | 10-Q | 2019-04-10 | 0001280776-19-000032 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost | Share-based Payment Arrangement, Plan Modification, Incremental Cost | USD | 1.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | USD/shares | 5.35 | 2018-01-01 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-04 | 0001280776-19-000025 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | USD/shares | 6.05 | 2018-01-01 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-04 | 0001280776-19-000025 |
| us-gaap | SharePrice | Share Price | USD/shares | 12.87 | 2019-06-30 | 2019 | Q2 | 10-Q | 2019-08-08 | 0001280776-19-000051 | |
| us-gaap | SharesIssuedPricePerShare | Shares Issued, Price Per Share | USD/shares | 5.5 | 2015-10-31 | 2016 | FY | 10-K | 2017-03-07 | 0001280776-17-000010 | |
| us-gaap | StockholdersEquity | Stockholders' Equity Attributable to Parent | USD | 104.47M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | StockholdersEquityNoteStockSplitConversionRatio1 | Stockholders' Equity Note, Stock Split, Conversion Ratio | pure | 0.025 | 2019-04-12 | 2020 | FY | 10-K | 2021-02-26 | 0001280776-21-000009 | |
| us-gaap | StockIssued1 | Stock Issued | USD | 0 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-02-23 | 0001280776-23-000004 |
| us-gaap | StockIssuedDuringPeriodSharesNewIssues | Stock Issued During Period, Shares, New Issues | shares | 460,336 | 2018-12-01 | 2018-12-31 | 2019 | Q2 | 10-Q | 2019-08-08 | 0001280776-19-000051 |
| us-gaap | StockIssuedDuringPeriodSharesStockOptionsExercised | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | shares | 0 | 2019-01-01 | 2019-03-31 | 2019 | Q1 | 10-Q | 2019-04-10 | 0001280776-19-000032 |
| us-gaap | StockIssuedDuringPeriodValueAcquisitions | Stock Issued During Period, Value, Acquisitions | USD | 39.40M | 2019-01-01 | 2019-12-31 | 2020 | FY | 10-K | 2021-02-26 | 0001280776-21-000009 |
| us-gaap | StockIssuedDuringPeriodValueConversionOfConvertibleSecurities | Stock Issued During Period, Value, Conversion of Convertible Securities | USD | 0 | 2025-04-01 | 2025-06-30 | 2025 | Q3 | 10-Q | 2025-11-13 | 0001280776-25-000017 |
| us-gaap | StockIssuedDuringPeriodValueEmployeeStockPurchasePlan | Stock Issued During Period, Value, Employee Stock Purchase Plan | USD | 86,000 | 2026-04-01 | 2026-06-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | StockIssuedDuringPeriodValueIssuedForServices | Stock Issued During Period, Value, Issued for Services | USD | 89,000 | 2018-01-01 | 2018-03-31 | 2019 | Q1 | 10-Q | 2019-04-10 | 0001280776-19-000032 |
| us-gaap | StockIssuedDuringPeriodValueNewIssues | Stock Issued During Period, Value, New Issues | USD | 5,000 | 2022-01-01 | 2022-03-31 | 2023 | Q3 | 10-Q | 2023-11-14 | 0001280776-23-000018 |
| us-gaap | StockIssuedDuringPeriodValueOther | Stock Issued During Period, Value, Other | USD | 0 | 2014-01-01 | 2014-12-31 | 2016 | FY | 10-K | 2017-03-07 | 0001280776-17-000010 |
| us-gaap | StockIssuedDuringPeriodValueStockOptionsExercised | Stock Issued During Period, Value, Stock Options Exercised | USD | 289,000 | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | TangibleAssetImpairmentCharges | Tangible Asset Impairment Charges | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | TemporaryEquityAccretionToRedemptionValueAdjustment | Temporary Equity, Accretion to Redemption Value, Adjustment | USD | 0 | 2016-01-01 | 2016-12-31 | 2016 | FY | 10-K | 2017-03-07 | 0001280776-17-000010 |
| us-gaap | TemporaryEquityDividendsAdjustment | Temporary Equity, Dividends, Adjustment | USD | 0 | 2016-01-01 | 2016-12-31 | 2016 | FY | 10-K | 2017-03-07 | 0001280776-17-000010 |
| us-gaap | UnrecognizedTaxBenefits | Unrecognized Tax Benefits | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001280776-26-000005 | |
| us-gaap | UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions | USD | 0 | 2018-01-01 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-04 | 0001280776-19-000025 |
| us-gaap | UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions | Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions | USD | 108,000 | 2018-01-01 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-04 | 0001280776-19-000025 |
| us-gaap | UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate | Unrecognized Tax Benefits that Would Impact Effective Tax Rate | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001280776-26-000005 | |
| us-gaap | ValuationAllowanceDeferredTaxAssetChangeInAmount | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | USD | 2.80M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001280776-26-000005 |
| us-gaap | ValueAddedTaxReceivableCurrent | Value Added Tax Receivable, Current | USD | 410,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 | |
| us-gaap | WeightedAverageNumberOfDilutedSharesOutstanding | Weighted Average Number of Shares Outstanding, Diluted | shares | 38.51M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |
| us-gaap | WeightedAverageNumberOfShareOutstandingBasicAndDiluted | Weighted Average Number of Shares Outstanding, Basic and Diluted | shares | 21.56M | 2021-01-01 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-04 | 0001280776-21-000023 |
| us-gaap | WeightedAverageNumberOfSharesOutstandingBasic | Weighted Average Number of Shares Outstanding, Basic | shares | 38.51M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001280776-26-000021 |